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ABSTRACT  
. It is believed that telomerase is involved in tumorigenesis and telomerase 
activation in general signifies immortalization of cells. Li order to investigate the 
role of telomerase in the pathogenesis of different grades and subtypes of brain 
tumor, telomerase activity from a broad spectrum of astrocytic and nonastrocytic 
gliomas (n=131) was examined. Telomerase activity was detected in grade H and 
higher grade tumors but absent in grade I tumors. All pilocytic astrocytomas 
(n=16), dysembryoplastic neuroepithelial tumor (n=l) and pleomorphic 
xanthoastrocytomas (n=2) were telomerase negative. Two of 19 (10.5%) 
ependymal tumors, 3 of 11 (27.3%) oligodendrogliomas, 7 of 12 (58.3%) anaplastic 
oligodendrogliomas, 1 of 4 (25%) oligoastrocytomas and 1 of 2 (50%) anaplastic 
oligoastrocytomas had detectable telomerase activity. Higher expression 
frequency in anaplastic than in grade II oligodendroglial tumors suggests the role of 
telomerase activation in progression of these tumors, though the difference was not 
statistically significant. On the other hand, the similar telomerase expression 
frequencies in grade II (23.1%), grade III (23.1%) and grade TV (26.3%) 
astrocytomas suggest that telomerase activation was probably an early event in the 
molecular genesis of astrocytomas. Besides telomerase activity, the role of 
telomere and telomerase regulation in non-astrocytic gliomas was further 
investigated. The telomere length and the m R N A expression of telomerase reverse 
transcriptase gene (hTERT) and associated protein (hTEPl) were examined in 26 
oligodendroglial and 15 ependymal tumors which were not previously studied in 
ii 
the literature. There was no statistical difference between mean telomere length in 
telomerase-positive and telomerase-negative tumors although a slightly shorter 
length was observed in telomerase-positive oligodendroglial tumors (11.50 kb vs. 
� 
13.05 kb; P=0.424). hTEPl m R N A was widely expressed in both telomerase-
positive and telomerase-negative oligodendroglial and ependymal tumors. On the 
other hand, hTERT m R N A expression was highly correlated with telomerase 
activity status. It was expressed in 8/8 (100%) and 2/2 (100%) telomerase-positive 
oligodendroglial and ependymal tumors respectively while 3/6 (50%) of 
telomerase-negative oligodendroglial tumors and no telomerase-negative 
ependymal tumors showed expression. This suggested the critical role ofhTERT 
in determining the enzymatic activity of human telomerase in non-astrocytic 
gliomas. It has recently been proposed that both pl6/Rb pathway inactivation and 
telomerase activity were required for epithelial cells immortalization. However, 
no correlation between the pl6 or pRb protein expression with telomerase activity 























(11.5kbvs.l3.05kb;P=0.424) ‘ 二者間差距並無統計學上顯著意義。作爲 
端粒脲謂節因子之一的hTEPl ,它的 m R N A S端粒腺陰性和陽 | 4的少 
枝細胞瘤和室管膜瘤均有表達。而作爲另一端粒腙m節因子的 hTERT , 
^. 
它的 m R N A表達與端粒活性呈正相關。 8/8 (100%)的端粒臈隱性少 
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L1. Central Nervous System Tumors  
Central nervous system (CNS) tumors contain different types of tumors which 
show distinct histologic features. Classification of C N S tumors is based mainly on 
cell types and tissue patterns that are observed under conventional light microscopy. 
Besides, immunocytochemistry (i.e. expression of marker antigens) also serves as a 
reference. CNS tumors are classified and graded using World Health Organization 
(WHO) grading system which has a malignancy scale ranging across a wide range 
variety of intracranial neoplasms. 
The average annual incidence of cancers of nervous system in Hong Kong is 
2.5 per 100,000 population for males and 2.2 per 100,000 population for females 
CNg et aL，1988; Poon & Ng, 1992). Hong Kong Chinese have a lower incidence 
rate when comparing to the incidence rate of primary tumors in all age groups of 
Caucasians in United States which is about 10 per 100,000 population. In children, 
brain tumors constitute the second most common neoplasms in the westem 
countries (Poon & Ng, 1992; Freeman, 1985). 
A study reviewing 168 CNS tumors from our hospital showed that 90% of the 
tumors were intracranial while the rest was situated at spinal cord fNg et al., 1988). 
1 
I 
Table 1.1 shows the histological distribution of all brain tumors managed at the 
neurosurgical unit of our hospital from 1984 to 1992 (Poon & Ng, 1992). Gliomas 
of all forms constituted 30 % of the whole series with male to female ratio 1:1.5. 
，， 
Fifty percent of the gliomas collected were glioblastomas. It showed that gliomas 
constituted a smaller proportion of C N S tumor in Hong Kong Chinese than in 
Caucasians and Thais whereas gliomas generally constituted more than 40 % of 
primary CNS tumors QS[g et al., 1988). The average age of patients with malignant 
astrocytomas, including anaplastic astrocytomas and glioblastomas was 41 years. 
It was one decade younger than that reported in the western countries and 19% 
occurred in patient less than 20 years of age (Poon & Ng, 1992; Ng et al.，1988). 
In contrast to gliomas, the percentages of meningiomas, vascular malformations 
and hemangioblastomas were higher than those in the westem countries whereas 




. Table I.1. Histological types of all brain tumors managed at the neurosurgical unit of 
Prince ofWales Hospital ’ May 1984-April 1992 (Poon & Ng, 1992) 
Tumor type 1 ^ % 
Primary/Benign Meningioma 112 20 
Nerve sheath tumor 74 14 
Pituitary adenoma 47 9 
Haemangioblastoma 16 3 
Craniopharyngioma 13 2.3 
Primary/Malignant Glioma 164 30 
Medulloblastoma 20 4 
Germ cell tumors 11 2 
Lymphoma 8 1 
Chordoma 3 0.6 
Neuroblastoma 2 0.4 
Secondary/Malignant Metastasis 72 13.0 
Others 4 0.7 
Totals 546 100.0 
3 
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L2. Histopathological Classification of Gliomas  
、 Among different kinds of C N S tumors, gliomas from the category of tumors 
of neuroepithelial tissue constituted the largest group. They can be further divided 
into astrocytic and non-astrocytic tumors according to their glial cell types. 
1.2.1. Astrocytic Tumors 
Astrocytic tumors play a very important role in C N S tumors. They are 
gliomas of astrocytic origin and cover a wide range of neoplasms that differ in their 
location within the CNS, age and gender distribution, growth potential, extent of 
invasiveness, morphological features, tendency for progression and clinical course. 
Diffuse astrocytomas, pilocytic astrocytomas and pleomorphic xanthoastrocytomas 
are described below. 
1.2.1.1. Diffuse Astrocytomas 
Diffusely infiltrating astrocytomas are the most frequent intracranial 
neoplasms. They account for more than 60% of all primary brain tumors and nearly 
75% ofcerebral astrocytic tumors (Kleihues & Cavenee，1997; Thomas & Graham, 
1995). Diffuse astrocytic tumors may arise at any site in the CNS, and usually 
manifest clinically in male adults (Thomas & Graham, 1995). They have a wide 
4 
( 
range of histological features and biological behaviors and show a diffuse 
infiltration of adjacent and distant brain structures that is largely irrespective of 
histological grade. Generally, they tend to progress to more malignant grade. 
n, 
They are named differently according to their tumor grade: low grade diffuse 
astrocytomas, anaplastic astrocytomas and glioblastomas. 
1.2.1.1.1. Low Grade Diffuse Astrocytomas 
Low grade diffuse astrocytomas are also termed as well differentiated 
astrocytomas. They correspond to W H O grade II (Kleihues et al., 1993) and 
represent approximately 25 % of all gliomas in the cerebral hemisphere (Kleihues 
& Cavenee, 1997). These lesions typically affect young adults of mean age about 
34 years (Kleihues & Cavenee, 1997) and most commonly develop supratentorially 
in the cerebrum in both children and adults. Astrocytomas can be characterized 
further by similarities to the basic morphological types of astrocytes in normal and 
reactive brain, i.e. fibrillary, gemistocytic and protoplasmic. 
1.2.1.1.2. Anaplastic Astrocytomas 
A diffusely infiltrating astrocytomas with focal or dispersed anaplasia, marked 
proliferative potential and correspond to W H O grade III (Kleihues et al., 1993). 
The mean age of patients is 41 years and males are frequently more affected 
(Kleihues & Cavenee, 1997). Generally, anaplastic astrocytomas have a less 
5 
( 
fibrillary matrix than well-differentiated astrocytomas and a preference for cerebral 
hemisphere more than other diffuse astrocytomas. Besides, they show an ill-
defined mass of low density with partial contrast enhancement. Increased 
^. 
cellularity, nuclear size, variation in shape and dispersion of chromatin, mitotic 
activity are also associated. GFAP expression is not consistent in all tumor cells 
and the growth fraction is usually 5-10 % (Kleihues & Cavenee，1997). 
1.2.1.1.3. Glioblastomas 
Glioblastomas (GBM) are the most malignant astrocytic tumors and composed 
of poorly differentiated neoplastic astrocytes with areas of vascular proliferation 
and / or necrosis. 
G B M and its variant correspond to W H O grade IV (Kleihues et al., 1993)， 
account for approximately 12-15% of all intracranial neoplasms and 50-60% of all 
astrocytic tumors (Kleihues & Cavenee,1997). They preferentially affect adults 
and occur most often in the cerebral hemispheres. G B M exhibit extensive but 
variable cytoplasmic and nuclear pleomorphism. The cellular forms range from 
scant cytoplasm with round to oval, densely hyperchromatic nuclei to bizarre, 
multinucleated cells. Macroscopically，GBM are poorly delineated and central 
necrosis (Fig. 1.1) may occur as much as 90% of the total number mass. The 
regional heterogeneity of G B M is marked. Mitotic activity (Fig. 1.1) and the 




Fig. I.1. Glioblastoma multiforme. Necrosis and mitosis 
are indicated by N and M respectively (H & E; X100). 
7 
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geographic extent of GFAP reactivity is highly variable in G B M . According to a 
recent concept, G B M s can be further divided into primary and secondary types (von 
Deimling et aL, 1993). 
Primary GBM 
They account for the vast majority of these tumors in older people of mean age 
about 55 years (Kleihues & Cavenee, 1997) and have a shorter clinical history 
without evidence of a pre-existing, less malignant precursor lesion. It was 
suggested that primary G B M is associated with epidermal growth factor receptor 
{EGFR) amplification, loss of heterozygosity (LOH) of chromosome 10 without 
TP53 gene mutations. 
Secondary GBM 
They are glioblastomas of long clinical duration, often develop over months or 
years, from low-grade diffuse or anaplastic astrocytomas and typically affect young 
adults (aged 30-45 years) (Kleihues & Cavenee，1997). Evidences showed that 
secondary G B M is associated with TP53 mutations and L O H of chromosome 17p. 
Other Variants 
Giant cell glioblastomas are rare variants, account for less than 10 % of all 
brain tumors and up to 5 % of G B M (Klehues & Cavenee，1997). They have a 
8 
marked predominance of bizarre, multinucleated giant cells, and, on occasion, an 
abundant stromal reticulin network. 
n_. 
Gliosarcomas are variants with a sarcomatous component, constitute 
approximately 2% of all glioblastomas and are usually located in the cerebrum. 
Histologically, the relative proportions of glial and sarcomatous vary, and the 
sarcomatous elements may overwhelm the primary glial neoplasm to complicate 
diagnostic interpretation. 
L2.1.2. Pilocytic Astrocytomas 
Pilocytic astrocytomas are circumscribed astrocytomas, composed of variable 
portions of spongy and compact tissues. They commonly occur in children and 
young adults and correspond to W H O grade I (Kleihues et al.，1993). 
Pilocytic astrocytomas arise throughout the central nervous system from the 
optic nerve to conus medullaris. Histologically, these tumors are composed of a 
biphasic population of stellate and elongate bipolar astrocytes with only moderate 
cellularity. Rosenthal fibres, granular eosinophilic or hyaline bodies, microcystic 
degeneration and vascular hyalinization are the typical degenerative features. They 
are remarkable in maintaining their grade I histological status over years and even 
decades. Studies with Ki67/MIB-1 also show a low proliferative potential. 
9 
1.2.1.3. Pleomorphic Xanthoastrocytomas 
They are astrocytic neoplasms with a relatively favorable prognosis, typically 
%. 
occur in children and young adults. They correspond to W H O grade II (Kleihues et 
al., 1993) and account for less than 1% of all astrocytic neoplasms (Kleihues & 
Cavenee, 1997). They usually locate superficially in the cerebral hemispheres with 
involvement of meninges, and have a pleomorphic histological appearance 
expressing GFAP. The abundance of reticulin stroma is a striking feature that 
delineates fascicles of cells and is variably distributed between single tumor cells. 
Some cases showed that these tumors may progress to anaplastic astrocytoma or 
G B M (Klehues & Cavenee, 1997; Thomas & Graham，1995). 
1.2.2. Non-Astrocytic Tumors 
Oligodendroglial tumors, ependymal tumors and dysembryoplastic 
neuroepithelial tumors are described below: 
1.2.2.1. Oligodendroglial Tumors 
Oligoden drogliomas 
They are diffusely infiltrating tumors and predominantly composed of cells 
morphologically resembling oligodendroglia (Fig, L2). They correspond to W H O 
10 
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Fig. I.2. Oligodendroglioma. It shows the characteristic halo 
cytoplasm surrounding the nuclei (H & E; X 100). 
11 
grade II histologically (Kleihues et al., 1993). Oligodendrogliomas usually develop 
slowly over a period of years, represents 5% - 15% of intracranial gliomas (Thomas 
& Graham, 1995) and arise preferentially in the white matter of the cerebral 
«1. 
hemispheres (Kleihues & Cavenee， 1997). Focal calcification is a 
histopathological hallmark of oligodendrogliomas but there is no 
immunocytochemical marker available that would allow the specific and sensitive 
recognition of human oligodendroglial tumor cells. Nuclear morphology and a 
delicate matrix composed of indistinct cellular processes are the principle of 
cytological features to distinguish oligodendrogliomas from astrocytomas. The 
most constant histopathological feature of these tumors is the conspicuous network 
of delicate capillaries distributed in a pseudolobular pattern. Oligodendrogliomas 
generally recur locally. Malignant progression on recurrence is not uncommon 
although it is thought to be less frequent than in diffuse astrocytomas. 
Anaplastic Oligodendrogliomas 
They are oligodendrogliomas with focal or diffuse signs of anaplasia. 
Increased cellularity, nuclear atypia, cellular pleomorphism, high mitotic activity, 
microvascular proliferation and necrosis are associated. Anaplastic 
oligodendrogliomas (Fig. I.3) correspond to W H O grade III histologically 
(Kleihues et al., 1993). They also arise preferentially in adults and share with 
grade II oligodendrogliomas a preference for the frontal lobe. Anaplastic 
oligodendrogliomas often contain significant admixture of neoplastic astrocytes and 
12 
_ 1 
Fig I.3. Anaplastic oligodendroglioma. Increased 
cellularity and mitosis (indicated by arrowheads) are 
demonstrated (H & E; X 100). 
13 
may progress to highly anaplastic tumors that may be morphologically 
indistinguishable from glioblastomas. 
，， 
Oligoastrocytomas 
They are the most common mixed gliomas and composed of a conspicuous 
mixture of two distinct neoplastic cell types (Fig. I.4) that morphologically 
resemble the tumor cells in oligodendroglioma or low-grade diffuse astrocytoma of 
W H O grade 11. The two components may either be diffusely intermingled or 
separated into distinct areas. Oligoastrocytomas are graded as W H O grade II 
(Kleihues et al., 1993). These tumors are found to be arised preferentially in the 
cerebral hemisphere, affect males slightly more frequently. Clinically, 
oligoastrocytomas present with symptoms and signs similar to those described for 
astrocytomas and oligodendrogliomas. They are moderately cellular neoplasms 
with low mitotic activity and no special features that would allow distinction from 
other W H O grade II gliomas either neuroradiologically or macroscopically. 
Besides, the oligodendroglial and astroglial components in oligoastrocytomas show 
the same immnoreactivity patterns as pure oligodendrogliomas and astrocytomas 
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Anaplastic oligoastrocytomas are rapidly growing tumor with histological 
, signs of anaplasia in the form of increased cellularity, nuclear atypia, 
pleomorphism, and increased mitotic activity. In addition, vascular endothelial 
proliferation and necrosis may be present. They are graded as W H O grade III 
(Kleihues et al., 1993) and are predominantly hemisphere. Similar to 
oligoastrocytomas, there are no consistent features that would allow macroscopic 
distinction of anaplastic oligoastrocytomas from other anaplastic glioma types. 
Anaplasia may be restricted to either the oligodendroglial or astroglial component 
though anaplasia is evident in both components in most tumors. The prognosis of 
these tumors is relatively poor but considerably better than G B M . 
1.2.2.2. Ependymal Tumors 
.1 
Ependymomas 
Ependymomas are predominantly composed of neoplastic ependymal cells, 
manifest preferentially in children and young adults, and correspond to W H O grade 
II histologically (Kleihues et al., 1993). They represent between 2 % and 6 % of 
gliomas (Thomas & Gmham, 1995) and commonly occur in the ventricles. 
Ependymomas are moderately cellular, with perivascular pseudorosettes (Fig. I.5) 
and ependymal rosettes as the key histological features and exhibit low mitotic 






Fig. 1.5. Ependymoma. The pseudorossetes and ependymal : 
t 
rossetes are the hallmark of ependymomas (H & E; X 100). 
17 
i 
arrangements of other glial tumors by their long-tapering, fibrillated processes 
extending to the vessel wall. They are also focally immunoreative for GFAP and 




These variants show evidence of advanced anaplasia, e.g. nuclear atypia, 
• ] 
marked mitotic activity (Fig. I.6A), high cellularity and, less consistently, i 
. I 
microvascular proliferations and necrosis. They correspond histologically to 
W H O grade III (Kleihues et al.，1993). They show a greater tendency for invasion 
i  'j 
of adjacent brain structures. However, the histopathological definition of 1 
anaplastic ependymoma has remained a controversial issue. 
• i| 
:¾ 
Myxopapillary Ependymomas '' 
These variants (Fig. I.6B) develop almost exclusively in the conus-cauda-
filum termnale region. They correspond to W H O grade I (Kleihues et al., 1993) 
and characterized by cuboidal, GFAP expressing tumor cells. Histologically, they 
contain an admixture of highly fibrillated and epithelial cells with an abundant 
supportive connective tissue stroma. These tumors affect males and younger 
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Fig • 1.6. Ependymal tumor. (A) Anaplastic ependymoma: high 
mitotic activity (indicated by arrowhead) (H & E; X 200). (B) 




They are intraventricular mass which are composed of nests of tumor cells 
、 embedded in a dense fibrillary matrix. They correspond to W H O grade I 
(Kleihues et al., 1993) and affect middle-aged and elderly males most frequently. 
These tumors are small, have very low mitotic ativity and many cells contain 
bundles of intermediate filaments microscopically. Conspicuous cellular 




L2.2.3. Dysembryoplastic Neuroepithelial Tumors 
They are rare, benign, usually supratentorial mixed glial-neuronal neoplasms. 
They are characterized by the multinodular architecture, a predominantly 丨 
{ 
intracortical location and graded as W H O grade I histologically (Kleihues et al., 
1993). The cortical topography of these lesions is an important criterion for 
' ' 
differentiating between these tumors and gliomas. Three histological variants have 
been distinguished as: "complex", “simple” and so called "non-specific". 




L3. Molecular Genetics in Gliomas  
In 1971, Alfred Knudson proposed a two-hit hypothesis. It suggests that two 
%. 
genetic events are required for tumorigenesis. In familial cases, one mutation is 
inherited and the other is somatic mutation. In sporadic cases, tumors arise from 
two independent somatic mutations of the same gene. The two hit hypothesis 
explains the mechanism of tumorigenesis in some inherited tumor syndromes e.g. 
familial retinoblastoma, but a multistep model for tumor development has emerged 
and is widely accepted now. Molecular analysis in gliomas has already pointed to 丨 
I 







p53 on chromosome 17p watches over the integrity of the genome by keeping 
f' 
the cell from duplicating itself, via G1 arrest or suicide. Loss of heterozygosity of 
chromosome 17p frequently occurs in astrocytic tumors regardless of their 
histological grade (el-Azouzi et al., 1989; James et al., 1990). p53 mutation is also 
commonly observed in high grade astrocytic gliomas. However, the mutation rate 
in low grade astrocytomas is variable in different studies and whether p53 gene 
mutation is associated with malignant progression or with tumor initiation is still 
controversial (Hwang et al., 1999; Reifenberger et al., 1996; Louis 1994). 
21 
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Loss of heterozygosity of chromosome 17p was observed in 12-40% of 
oligodendrogliomas and 20-35% of oligoastrocytomas (Ohgaki et al., 1991; Hagel 
et al.，1996; Maintz et al., 1997; Zhu JJ et al., 1998). Mutational analysis 
� 
demonstrated that p53 mutation was observed in 42% of oligoastrocytomas and 4 
% of ependymomas (Tong et al., 1999). 
Chromosome 10，PTEN and DMBT1 
L O H of chromosome 10 occurs in more than 70% of G B M but the incidence ! 
1 
rate is much lower in anaplastic astrocytomas or anaplastic oligodendrogliomas ‘ 
i 
(Lin et al., 1998). PTEN gene on chromosome 10q23 has been proposed to be a ‘ 
candidate tumor suppressor gene (Li et al., 1997). Mutational analysis of the 
I. 
PTEN gene in gliomas demonstrated that PTEN mutation occurred in 14%-27% i' 
', 
G B M , 7 % anaplastic astrocytomas, 3% pilocytic astrocytomas and 9 % 
••( 
oligodendrogliomas (Duerr et al., 1998; Zhou et al., 1999). No mutation was 
i^ 
found in other gliomas analyzed including low grade astrocytomas, 
oligoastrocytomas and ependymomas in these studies (Duerr et al., 1998; Zhou et 
al., 1999; Tong et al., 1999). These findings suggest that PTEN plays an 
important role in the pathogenesis of high grade astrocytoma as a late event. High 
frequency of allelic deletions was detected at the proximal 10q23 region in both 
oligodendroglial and ependymal tumors by Tong et al (1999) also suggested that 
the telomeric end of chromosome 10q could be involved in the development and 
anaplastic transformation of these tumors. Besides PTEN, DMBT1 is another 
22 
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candidate tumor suppressor gene on chromosome 10q25-26. The fact that there is 
hemizygous deletion at 10q25 -qtel in low grade astrocytomas and 
oligodendrogliomas suggests the existence of a putative suppressor gene involved 
� 
in glial tumorigenesis (Maier et al., 1998). 
Other Chromosome Loss 
) 
Chromosome 19q is another common allelic loss region in gliomas. Allelic 
loss was found in all grade of astrocytomas, oligodendrogliomas and j 
oligoastrocytomas (Zhu JJ et al.，1998; von Deimling et al.，1994). High ! 
frequency L O H regions are also identified on chromosome arm lp in | 
• •丨 
oligodendrogliomas (Zhu JJ et al., 1998). Besides 19q and lp loss, chromosome 丨 
I: 
22q which contains the neurofibromatosis type 2 tumor suppressor gene {NF2) is |'| 
< 




et al., 1995). Findings that L O H on chromosome 11 in about 30% high grade ! 
f‘ 
gliomas also suggest that a putative tumor suppressor gene might be located on this 
chromosome (Zhu JJ et al., 1998; Sonoda et al., 1995b). 
EGFR and Other Oncogenes 
The most common oncogene abnormality in gliomas is the epidermal growth 
factor receptor, EGFR. Studies showed that amplification of this gene, which 
resides on chromosome 7, occurs in 40-50% malignant astrocytomas (Hayashi et 
al., 1997; Chaffanet et al., 1992). The p53 mutations or L O H of 17p are almost 
23 
i 
never found in G B M s with EGFR amplification, thus two subtypes of G B M was 
proposed (Kleihues & Ohgaki，1997; Louis, 1997; Watanabe et al., 1996; von 
Deimling et al., 1993). Type 1 or secondary G B M have frequent p53 mutations 
^ 
but no EGFR amplification, whereas the type II or primary G B M frequently have 
amplified or overexpressed EGFR but no p53 mutations. Besides, amplification of 
EGFR in G B M is always associated with loss of chromosome 10 (Fults et al., 1990; 
von Deimling et al., 1992). Besides EGFR, other oncogenes that are reported to be ‘ 
involved in the development of astrocytic tumors include PDGF, erB, rosI, H-ras, 
i 
N-ras,fos, N-myc, gli and MDM2 Q^g & Lam.，1998). 
i 
i 
Cell Cycle Regulators - pl6，pl5, CDK4 and pRb 
• 'i ；I 
<: 
Cell cycle (Fig 1.7) consists of S phase and M phase for D N A synthesis and 
••{. 
mitosis respectively. The period between M and S is called G1 (for growth and 
,.� 
preparation of the chromosome for replication) and that between S and M is G2 
(preparation for mitosis). Various genes encoding regulatory activities that govem 
the mammalian cell cycle, particularly the progression of quiescent cells through 
G1 into S phase, are targets for genetic alterations that underlie the development of 
many human neoplasms. These include members of the cyclin gene family and 
cyclin-dependent kinase ii^ iibitors. 
I 

















































































































































































































































































































































































































































The classical cyclins undergo periodic accumulation and destruction in phase 
with the cell cycle, thus providing a mechanism whereby the activities of the 
various cyclin-kinase complexes are regulated throughout the cycle. The activity 
� 
of the kinases is in tum regulated by phosphorylation and dephosphorylation, 
providing a further tier of control. 
The retinoblastoma gene, Rb’ is one of the negative regulators (Fig.I.7). 
Evidence suggests that in normal cells, Rb must be inactivated in order for the 
cells to leave G1 phase and begin D N A synthesis. The evidence also suggests that 
[ 
it is the unphosphorylated or hypophosphorylated forms of Rb that are functional 
I 
and that the restraining influences of Rb is alleviated by phosphorylation 丨 
1 
I' 
(Goodrich & Lee, 1993; Ewen, 1994). The oncogenenic subtypes of human ^ 
.i 
• i ' i 
papilloma virus (HPV), E7 protein bind peferentially to under-phosphorylated Rb ； 
and promote progression into S phase by preventing Rb from performing its normal 
i,'l •‘] 
functions. ' 
The phosphorylation and inactivation of Rb are accomplished by cyclin-Cdk 
complexes. The earliest of these would be the D cyclins (cyclins Dl-D3) in 
conjunction with their major catalytic partners, Cdk4 and Cdk6, to phosphorylate 
Rb in vitro (Ewen et al., 1993; Kato et al., 1993; Serrano et al.，1993). pl6^K4a 
(Serrano et al., 1993) and pl5^^^^^ (Hannon & Beach, 1994) are two cyclin-
dependent kinase inhibitors (Fig.L7). They form specific binary complexes with 
CDK4 and CDK6 and inhibit the kinase activity of D-type cyclin-dependent 
26 
i 
CDK4。 Since the loss of these inhibitors would lead to an increase in kinase 
activity and promote cell cycle progression, they are candidates for tumor 
suppressor genes. The expression of pl6 is inversely correlated with the presence 
> 
of functional Rb. These data suggest that pl6 is part of a feedback loop that 
regulates Rb (Parry et al., 1995). It also implies a common mechanism of 
tumorigenesis in which loss of pl6, over-expression of cyclin D1 and loss ofRb are 
functionally analogous. : 
I ； 
j 
pl6 gene deletion was observed in about 40% of G B M and 20% of anaplastic 
I 
astrocytomas but not in low grade astrocytomas (Piva et al., 1998; Ichimura et al.， 
i ] 
• i 
1996). For non-astrocytic glioma, only 1 of 17 (6%) of oligodendrogliomas \ 
'i 
i 
showed pl6 gene mutation and but no homozygous deletion of pl6 and pl5 gene 
was observed in oligodendroglioma and ependymoma. These findings indicate 
,i 
that pl6 deletion is responsible for malignant progression of astrocytomas. On the 丨 
other hand, hypermethylation and mutation ofpl6 gene is uncommon in astrocytic ' 
tumors (Schmidt et al.，1997). 
Astrocytomas that do not have pl6 gene deletion often show gene 
amplification and increased expression of CDK4, the target for pl6 inhibition (He 
et al., 1994; Sonoda et al., 1995a). Allelic loss of chromosome 13q at the Rb gene, 
Rb gene mutations and loss of pRb expression were noted in 33% of G B M and 
25% of anaplastic astrocytomas, and pl6 or Rb alteration was inversely correlated 
in these tumors (Ueki et al., 1996). Rb gene deletions (Lee et al., 1995) but no 
27 
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CDK4 or Cyclin D1 amplification was observed in oligodendrogliomas and 













I.4. Telomeres and Telomerase  
Cancer is believed to be caused by multiple mutations that cumulatively 
subvert the normal growth of a cell. Individual types of cancer may be featured by 
alterations in characteristic sets of genes that are briefly described in Section I.3. 
Besides alterations of these genes, the activation of the enzyme telomerase is also 
J 
believed to be involved in the tumorigenesis recently. 
L4A, History ! 
’i 
In 1912, a culture of chick heart fibroblast cells was established by Alexis | 
I 
Carrel, and surprisingly, it grew in the laboratory for 34 years (Greider, 1998) At 
;'i 
that time, people generally accepted that vertebrate cells can divide indefinitely in 
j 
culture. In 1961, Hayflick and Moorehead on the other hand found that fibroblast :j 
cultures derived from human skins would divide 40 to 50 times, and then stop and 
undergo senescences (Hayflick, 1998). Further investigation from Hayflick 
showed that it was the total number of divisions since birth that is important for cell 
senescences but not the total divisions in culture (Hayflick, 1998). Besides, 
subsequent work showed that Carrel's immortal chicken cell culture was not 
reproducible, after that, Hayflick's senescence model eventually became accepted. 
Generally, Hayflick's model raised two important question. First, what is the role 
ofcellular senescence in humans, and second, what tells cells to stop dividing? 
29 
i 
Actually, some discoveries between 1930s and 1940s shed the light on 
answering these questions. Muller and McClinstock were the first to recognize the 
specificity of the chromosomes ends which also called telomeres (Rhyu, 1995). 
� . 
Later, Blackbum found that these chromosome ends, or telomeres, are made of 
simple repeated D N A sequences (Blackbum & Gall, 1978). This motif was 
conserved throughout evolution suggesting a common mechanism might exist in 
eukaryotes for the maintenance of telomeres. Table 1.2 listed the telomeric 





Telomeres are the very ends of linear eukaryotic chromosomes. Human J; 
'i 
telomeres contain the repeat T T A G G G , which may be reiterated in tandem up to 15 ’ 
. , i 
kilobases. Besides these telomeric D N A sequences, another type, telomere-
• J 
associated sequences are also repetitive and are found both adjacent to and within '‘ 
the telomere (Klug & Cummings, 1997). These sequences vary between 
organisms, and their significance remains unknown. Generally, telomeres play a 
role in both chromosome structure and function. They mainly act to prevent 
aberrant recombination and degradation by interacting with associated protein to 
cap the chromosome ends. They may also be important for anchoring the 
chromosomes to the inner nuclear membrane. Besides, experiments show that 
mutating telomeric D N A sequences prevent chromosome separation in anaphase 
suggesting that the primary role of telomeres is to ensure correct mitotic 
30 
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Table 1.2. Telomeric repeat sequences in eukaryotes 
Group Organism Telomeric repeat (5, to 3, 
toward the end)  
Vertebrates Human, mouse, Xenopus T T A G G G 
n. 
Filamentous fungi Neurospora T T A G G G 
Slime molds Physarum,Didymium T T A G G G 
Dictyostelium AG( 1 -8) 
Kinetoplastid protozoa Trypanosoma, Crithidia T T A G G G , 
Ciliated protozoa Tetrahymena,Glaucoma T T G G G G 
Paramecium TTGGG(T/G) :| 
Oxytricha,Stylonychia, T T T T G G G G 丨 
Euplotes 丨 
i 
Higher plants Arabidopsis T T T A G G G | 
Insects Bombyx mori T T A G G 
i' 
Alga Chlamydomonas T T T T A G G G j 
11 
(' 
Fission yeasts Schizosaccharomyces TTAC(A)(C)G(l-8) 
pombe 
11 :ii 




segregation of sister chromatids (Blackburn et al., 1997). The estimation of 
telomere shortening per one cell generaton of 50-100 bp correlates well with the 
observed telomere lengths of 18-25 kbp and 8-10 kbp in young and senescent 
^. 
human fibroblasts respectively (Sedivy, 1998). Hastie et al (1990) and de Lange 
et al (1990) found that tumor samples had shorter telomeres than adjacent normal 
tissue, providing the first clue of a connection between telomeres and cancer. 
Besides the possible connection between telomeres and cancer, loss of telomeric 
D N A with replicative aging ofhuman somatic cells has also been documented both j 
;•; 
I 
in vitro and as a function of donor age in vivo (Harley, 1997). However, the role 
of telomeres in those accelerated aging syndromes are still under investigated. 
I 
L4,3. End Replication Problem 
.1」 
i. 、丨 
The discovery of the double-stranded structure of D N A and its semi- j 
/ 
conservative mode of replication lead to the recognization of another function of 
chromosomal ends (Olovnikov, 1973). Conventionally, the chromosome ends of a 
linear D N A duplex cannot be fully replicated by a D N A polymerase complex 
(Fig.I.8). While the synthesis can proceed normally to the end of the leading 
strand, a problem is encountered on the lagging strand. In general, D N A 
polymerase requires a short R N A primer sequences to begin D N A polymerization 
in the 5' to 3' direction (the lagging strand synthesis) for copying the strands of 
D N A primer to each cell division. After D N A polymerization, these R N A primers 
32 
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Fig.I.8. The end replication problem. Replication of a linear parent duplex 
Oieavy line) is shown. Lagging strand synthesis is discontinuous, consisting 
Okazaki fragments which initiate with a RNA primer (box). After RNA primer 
removal and Okazaki fragment extension and ligation, the most 5' Okazaki 
fragment will remain incomplete since the RNA primer cannot be rephced. If the 
5, terminal Okazaki fragment does not initiate directly opposite the 3, end of the 
template DNA, there will be additional bases incompletely replicated, 
(modified from Klug & Cummings’ 1997) 
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are degraded and the newly created gap is normally filled by adding a nucleotide to 
the existing 3'-OH group provided during discontinuous synthesis. However, the 
primers that are annealed to the extreme 3丨 end of each strand will never be replaced 
,. 
because there is no strand present to provide the 3'-OH group at the end of 
chromosome. This is known as the end-replication problem. This replication 
strategy also explains the progressive shortening of chromosomal D N A at the 3' 
I 




In 1984, Carol. W . Greider identified an enzyme, telomerase, to compensate , 
for the end-replication problem by adding telomeric repeats onto the chromosome ' 
j I 
i 
ends (Greider & Blackbum, 1985). Telomerase is a ribonucleoprotein (RNP) ； 
:丨1 
complex using a small part of an intrinsic R N A component of the enzyme as a j 
• / 
template for repeat synthesis. The major function of telomerase in vivo is to 
counterbalance the progressive shortening of the chromosome from its ends. In 
general, germ cells and some key stem cells are known to express telomerase 
catalytic activity whereas the majority of somatic cells lack it (Kim et al., 1994; 
Sedivy, 1998). The mechanism on how the telomeric repeats are added de novo to 
the 3’ end of chromosomes is illustrated in Fig I.9. Firstly, chromosomal D N A 
binds part of the template region in telomerase R N A which provides the template 
for elongating the 3’ end of the lagging strand. After that, the chromosome is 
34 
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Fig.I.9. Mechanism of synthesis of the G-rich strand of telomeric DNA by 
telomerase in Tetrahymena. (1) The 3' end of the telomeric DNA base-pairs 
with the complementary nucleotides in the CAACCCCAA template sequence 
in the telomerase RNA. (2) Elongation of the telomere by polymerization of 
dGTP and TTP (indicated by lower case letters), copying the RNA template. 
(3) Translocation of the newly elongated 3' end and repositioning on the 
template before (4) another round of polymerization, 
(modified from Blackbum, 1991) 
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translocated and repositioned to repeat the polymerization step. The process is 
reiterated to add multiple copies of the telomeric repeat sequences. These repeats 
appear to be capable of forming a "hairpin loop" (Fig.I.10) which is stabilized by 
負. 
unorthodox hydrogen bonding between opposite guanine residues (G=G). This 
creates a free 3'-OH end that, following removal of the R N A primer, can serve as a 
substrate for D N A polymerase I to fill the gap and solve the end-replication 
problem. 
] 





Recently, studies show that telomerase is composed of a R N A component 
ij 
ii 
(hTR) and a catalytic subunit hTERT (Human Genome Data Base has approved the 
name hTERT for the human gene which have been called hTRT or hEST2 : 
previously). Besides, telomerase-associated protein hTEPl (which have been 'j 
i'| 
called TLP1 or TP1 previously) and telomeric repeat binding factor TRF1 are also ' 
involved in telomerase mechanism. 
1.4.5.1. RNA Component 
The R N A component of telomerase was first identified in Tetrahymena by 
Greider and Blackburn (1989). After that, the genes specifying the R N A subunits 
of telomerase have been cloned from a wide variety of species, including human 
(Feng et al., 1995; Greider & Blackburn,1989). The length ofthe mature hTR 
36 
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Fig.I.10. Diagram of the "Hairpin Loop" structure . The enzyme 
telomerase directs synthesis of the TTGGGG repeated sequence resulting in 
the formation of a hairpin structure. This process adverts the creation of a 
gap during replication of the ends of linear chromosomes. The RNA primer 
is represented by a box. (Klug & Cummings，1997) 
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transcript is approximately 450 nucleotides, which differs from that in ciliates (153 
to 192 nucleotides) and saccharomyces cerevisiae (1.3kb). The template region of 
hTR encompasses 11 nucleotide (5 ‘ C U A A C C C U A A C ) complementary to the 
n. 
human telomere sequence (TTAGGG)n. The consequences of telomerase R N A 
template mutations have been studied in vivo and in vitro in ciliates, yeast and 
mammals (Greider, 1996; Prescott & Blackburn, 1997; Marusic et al., 1997). 
;l 
Several of these mutations affect enzymatic properties such as processivity, fidelity, 
proper termination of synthesis and even telomerase activity elimination. A study j 
'•'i 
1 
demonstrated that mutating the conserved motif of telomerase R N A gene from ., 
,i 
yeast would result in telomere elongation to up to 100 times their normal length | 





Besides studying the template domain, the functions of non-template 
ii 
telomerase residues in telomerase R N A of budding yeast was also examined (Roy i 
f' 
et al., 1998). It showed that deleting or mutating some regions would lead to 
inability to assemble into a stable RNP, altered R N A conformation or abolished 
enzymatic activity. Therefore residues far from the template might also play 
essential roles in the telomerase RNP and its activity both in vivo and in vitro. 
Initial testing using Northern blotting indicated that hTR levels were not good 
predictors for the presence or amount of telomerase enzyme activity (Avilion et al., 
1996). However, using in situ hybridization to detect hTR, different teams of 
investigators have shown that hTR levels correlate well with telomerase activity or 
38 
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proliferation activity in clinical samples (Yashima et al., 1997; Soder et al., 1997; 
Hiyama et al, 1998). 
>. 
1.4.5.2. Protein Component 
The protein components of telomerase were first identified in Tetrahymena 
(Collins et al., 1995). Two polypeptides of 80 kDa and 95kDa copurified with 
telomerase activity and the telomerase R N A were shown to form a stable, three 
component R N P complex with the telomerase R N A . Nucleic acid cross-linking 
and binding assays demonstrated that p80 specifically interacts with the telomerase 
R N A and p95 specifically interacts with telomeric primers. 
A gene encoding a mammalian homologue of p80 (TEPl/TPl/TLPl) has 
been cloned recently (Harrington et al., 1997; Nakayama et al., 1997). They 
exhibit an extensive amino acid similarity to protein p80, but they show a specific 
W D 4 0 repeat sequences in the COOH-terminus in contrast to p80. Besides, using 
a local sequence homology search method, a similarity between p80 and the human 
autoantigen R060 was shown in which antibodies to R060 immunoprecipitate the 
telomerase activity. Findings suggested that telomerase proteins were conserved 
from ciliates to humans. However, the specific mechanisms by which these 
proteins ¢)80, p95, TEP1) participate in telomerase function have not been defined. 
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1.4.5.3. Catalytic Subunit 
Most recently, two related proteins, Est2p from the yeast S. cerevisiae 
、 (Counter et al., 1997) and pl23 from the ciliate Euplotes aediculants (Linger et al., 
1997)，were identified as the catalytic subunits of telomerase in their respective 
species. These two proteins have no homology with p80 or p95. Both the yeast 
and Euplotes proteins harbor several sequence motifs that are the hallmarks of the 
catalytic regions of reverse transcriptase. Substitution of several residues in Est2p 
abolishes telomerase activity (Lingner et al., 1997; Counter et al., 1997). A human 
gene, hTERT/hEST2/hTR T, that shares significant sequence similarity with the 
telomerase catalytic subunit genes of lower eukaryotes was cloned later ^ sfakamum 
et al., 1997; Meyerson et aL, 1997). Sequence comparison of the different 
telomerase catalytic subunits reveals that they contain the conserved domains 
common to all known reverse transcriptase fNfakamura et al., 1997). Introduction 
of the gene encoding TERT into telomerase-negative normal fibroblasts induces 
telomerase activity and extends the life span in normal human cells fNakayama et 
al., 1998; Bodnar et al., 1998). hTERT is expressed at high levels in primary 
tumors, cancer cell lines, and telomerase positive tissues, but is detected in 
telomerase negative cell lines and differentiated telomerase negative tissues at very 
low level O^akamura et al., 1997). Moreover, the message is up-regulated during 
in vitro cellular differentiation. These observations suggest that the induction of 
hTERT m R N A expression is required for the telomerase activation that occurs 
during cellular immortalization and tumor progression. 
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1.4.5.4. Telomeric Repeat Binding Factor 1 
Many sequences can serve as primers for the human telomerase in vitro, but 
、 they do not promote formation in vivo (Collins, 1996). These results suggest that 
telomerase recognizes a chromosome substrate composed ofboth D N A and protein. 
Human telomere contains two distinct Myb-related proteins, TRF1 and 
TRF2 (Chong et al., 1995; Broccoli et al., 1997; Bilaud et al., 1997). These 
factors probably have different functions at telomeres because they show significant 
difference. The physiological role of TRF2 at telomeres are expected to be 
coordinated with TRF1 as the relative amounts of TRF1 and TRF2 m R N A s appear 
to be unchanged in a range of somatic and germline tissues (Bilaud et al., 1997). 
Human TRF1 gene is localized to chromosome 8 recently and evidence shows that 
this locus is alternatively spliced and at least three pseudogenes from TRF1 gene 
family are dispersed in the human genome (Young et al., 1997). It has been 
shown that TRF1 is involved in a regulating mechanism limiting telomere 
elongation by telomerase (van Steensel & de Lange, 1997). It has also been 
shown that long term overexpression of TRF1 in a telomerase-positive tumor cell 
line resulted in gradual and progressive telomere shortening suggesting that TRF1 
is a suppressor of telomere elongation (van Steensel & de Lange, 1997). It was 
suggested that the binding ofTRFl controls telomere length in cis by inhibiting the 
action of telomerase at the ends of individual telomeres (van Steensel & de Lange, 
1997) or by protecting against activation of telomerase independent pathways of 
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telomere elongation (Cooper et al., 1997). However, it cannot exclude the 
possibility that TRF1 modulate telomere length by altering the rate at which 
telomeres are shortened. 
� 
L4.6. Cellular Immortality and Aging 
As people recognized the presence of telomere and the enzyme telomerase, 
they proposed a theory that marginal telomeres induce cell immortality (Rhyu, 
1995). This theory suggests that reactivation of telomerase may enable cells to 
prolong their life span. The immortalization theory is illustrated using an in vitro 
model (Fig.Lll). Human cells in culture were shown that they undergo certain 
number of cell division before senescence. This first mortality stage (Ml) can be 
avoided by mutations in some tumor suppressor genes e.g. p53 or pl6 or the 
addition of specific viral D N A sequences capable of overriding the cellular growth 
control signals. The survivors ofMl may undergo an additional 50 divisions and 
enter the second mortality stage (M2), which is known as crisis. However, a 
subpopulation at very low frequency can pass through M 2 stage by activation of 
telomerase in these cells. Telomerase stabilizes the chromosome ends of these 
cells, allow them to propagate and become immortal. There are reports 
demonstrated the expression of telomerase catalytic subunit in presenescent human 
cells can extend the lifespan of the cultures significantly (Bodnar et al.，1998; 
Vaziri & Benchimol，1998). However, whether it is a representative model for 
cancer remains a matter of debate and most recently, people begin to believe that 
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II.】 一― T ? 1 
‘ A. In somatic cells, telomerase is off. Telomeres 
decline with each division. 
, 111 I 〇 = I III 
B* Multiple divisions lead to some critically short 
• telomeres. 
_ (Ezzm 
C. Cellular proteins detect critically short 
，r^^^ ^ ^ telomeres and initiate exit from cell cycle; 
%y Cells Senesce 
I : 藝 〈 D. Mutations of gene that detect chromosomal 
abnormalities or regulate cell cycle may allow a 
clonal population to escape senescence and 
continue dividing, causing further telomere loss 
and chromosome instability (fusion shown) 
1:1 CT ( () 11 
，^  ^ ^ ^ £. accumulated defects over �5 0 additional 
V y divisions 
11 cr~ 11 
F. Activation of telomerase in some cells stabilizes 
ends and allows a subpopulation to escape crisis. 
Despite excessive mutations, stabilized chromosomes 
can propagate. These cells are immortal 
Fig.I.ll. Model for telomere role in aging and immortality 
(Rhyu, 1995) 
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the mere presence of telomeric activity does not establish that a cell is immortal, 
but that it simply has the potential to be immortal (Holt et al., 1996). 
V 
Aging is a side effect of optimizing an organism's evolutionary fitness and 
one hypothesis concerning aging of regenerative tissues is cell senescence (Kipling 
& Faragher, 1999). Therefore, if telomerase is not activated in cells that undergo 
significant amount of division, e.g. red blood cells, skin, hair, endometrium or 
spermatids, a lethal aging system might be created. The main biological feature of 
Werner's syndrome, a human premature-aging disease, is accelerated cell 
senescence (Kipling & Faragher, 1999). A study suggests that telomeres may be 
co-opted by other aging system since telomerase activation has been shown to be 
under hormonal control (Meeker et al” 1996). 
L4.7. Detection of Telomerase Activity 
Several methods have been developed for the detection of telomerase activity 
in tissue samples and cell lines. They are described as below. 
1.4.7.1. Telomeric Repeat Amplification Protocol Assay 
In 1994, Kim et al developed an improved method for extraction and 
detection of telomerase activity. A detergent lysis method was improved to allow 
more uniform extraction of telomerase activity even at low cell numbers while 
telomerase extraction was done by hypotonic swelling and physical disruption of 
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7 Q 
cells required at 10 to 10 cells previously. To increase the sensitivity, speed, and 
efficiency of detecting telomerase activity, a polymerase chain reaction (PCR)-
based assay designated Telomeric Repeat Amplification Protocol (TRAP) was 
^. 
developed by Kim et al (1994). This method makes the large scale surveys of 
telomerase activity in human cells and tissues possible. 
In the first step of the reaction, telomeric repeats are synthesized onto the 
nontelomeric oligonucleotides TS (5'-AATCCGTCGAGCAGAGTT-3') by 
telomerase. These telomerase products are then specifically amplified by PCR 
with the downstream primer C X (5'-(CCCTTA )3CCCTAA-3') and the upstream 
primer TS. D N A synthesis by PCR and optimal annealing of the C X primer are 
shown in Fig.I.12. The sensitivity of TRAP assay can be as high as 10^ cells for 
detection of telomerase activity at 27 PCR cycles. 
1.4.7.2. Other Detection Methods 
The TRAP method has a number of limitations: these include a time-
consuming radioisotope labelling system and difficulty in quantifying the enzyme 
activity because of the amplification procedure. Therefore several new detection 
methods involving fluorescent-labeled primers and non-PCR-amplified assays have 
been developed. 
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STEP 1. Addition ofTelomeric Repeats By Telomerase 
’ TS-Telomerase Product 
5' - TS Telomeric Repeats 18¾¾¾!?¾^  
AATCCGTCGAGCAGAGTT ag ggttag ggttag ggttag - 3， 
• » * 
3,- A A TC CCATTC CCATTC CCATTCCC -5， 
^^^¾ 
奶 
STEP ii i^plifieati0fl efTS:Teteffl^ase PmAmt By PGR 
TS 
<aVi^A:-^JMMMMM:..':.:�-......:.-r-:v:jMnMMnMnnMmHMnBt B3BS BSD SW OOB OM OBM BOK P j^^ BlVe>^ 
^  
cx 
Fig.L12. PCR Amplification of telomerase extension products. Asterisks 
indicate designed mismatches in CX that reduce primer interaction. 
(Kim et al., 1994). 
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A non-radioisotopic and semiquantitative procedure for terminal repeat 
amplification protocol has been described by Ohyashiki et al (1996). This is a 
PCR-based method in which telomerase activity is represented by fluorocurves, 
、， 
with the height and area of each peak calculated automatically so that telomerase 
activity can be measured in real time. Another nonradioactive assay for measuring 
telomerase is the Telomerase PCR ELISA (Boehringer Mannheim). It combines a 
one-step/one tube TRAP assay with non-radioactive detection in a highly sensitive 
photometric enzyme-linked immunosorbent assay. The final color intensities are 
measured with a microtiter plate reader. Another report also demonstrated that it 
is able to advance the TRAP assay to an in situ assay (Ohyashiki et al., 1997). 
Using fluorescent telomerase primers and in situ PCR, telomerase activity can be 
detected at the cellular level. To solve the problem of PCR-based TRAP 
inhibitors, a non-PCR-based transcription-mediated amplification (TMA) and 
hybridization protection assay (HPA) to the measurement of telomerase activity 
was developed by Hirose et al (Hirose et aL, 1998). T M A is an isothermal system 
and can be performed in a heat block or water bath while H P A is a homogeneous 
assay using an acridinium ester-labeled probe and does not require radioactive 
material. 
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L4.8. An Overview of Telomerase Activity 
No telomerase activity is detected in most normal somatic human tissues but 
、 can be detected in tumor-adjacent somatic tissue samples (Kim et al., 1994). On 
the other hand, telomerase activity is present in normal human leukocytes, primitive 
blood stem cells, germline cells, epidermal layer of skin, transit amplifying cells of 
hair follicle and gastrointestinal stem cells (Hiyama K et al,1995; Shay & Wright, 
1996; Yasumoto et al., 1996; Hiyama et al., 1996b). Telomerase activity also can 
be detected at high levels in cord blood, newborn pheripheral blood cells, and in 
neonatal foreskin tissue (Shay & Wriglit，1996). Cultured fetal amniocytes have no 
detectable telomerase activity (Shay & Wright，1996). 
Benign disorders that are telomerase positive also have also been reported. 
Weak telomerase activity can be detected in hepatitis tissues and cirrhotic liver 
tissues (Tahara et al., 1995). Besides, breast fibroadenomas, gastric adenoma and 、 
colon adenoma are telomerase positive in approximately half of the tested samples 
(Rhyu, 1995; Breslow et al., 1997; Shay & Wright, 1996; Hiyama et al., 1996a; 
Sugino et al., 1996). As for the immortal cell lines, Kim et al (1994) showed that 
98 of 100 independent immortalized cell lines were telomerase positive. Soria et 
al (1998) summarized the expression frequency from more than 20 different tumor 

























































































































































































































































































































































































L4.9. Alternative Lengthening of Telomeres 
Immortalization of human cells in culture is usually associated with 
’ expression of telomerase activity. However, lengthening of telomeres has 
occurred in some cases even no telomerase activity is detected. There are 
evidences that an alternate mechanisms of maintaining telomere length in human 
tumors and tumor derived cell lines when telomerase is inactivated in these cases 
(Bryan et al., 1995; Murnane et al., 1994). 
The presence of alternative lengthening of telomeres (ALT) is deduced from 
the combination of no detectable telomerase activity in the TRAP assay and 
telomeres that have a characteristic heterogeneity of length as determined by 
terminal restriction fragment agarose gels. Most of these immortal human 
fibroblasts that do not express telomerase activity have particular long telomeres 
(Bryan et al.，1995). It suggests that recombinational mechanisms are involved in 
this alternate pathway for telomere mainteinance (Holt et al., 1996). 
About 3% to 7 % of tumor-derived cell lines showed ALT and it was higher 
in fibroblastic-derived tumors than in epithelial-derived malignancies (Bryan et al., 
1997). Although ALT seems to be present in only a small proportion of tumors, it 
is possible that in tumors it is subjected to effective telomerase inhibition there 
would be a strong selection pressure for the emergence of treatment-resistant cells 
via the activation of ALT. Such an event would be even more problematic if 
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telomerase and alternative telomere-lengthening mechanisms coexist in cancer 
cells. These questions and the importance of A L T in human carcinogenesis must 
be determined in future preclinical and clinical trials. 
>. 
L4.10, Telomeres Suppressor Gene 
The senescence programe could be activated by a single pathway or by 
multiple, independent pathways. Since telomerase is proposed to be re-expressed 
in tumor or immortal cells to extend the shortened chromosomal ends, a genetic 
mechanism for repressing telomerase activity is proposed in normal somatic cells 
while immortal tumor cells are considered to have mutated, inactivated or lost 
putative repressor gene (Oshimura & Barrett, 1997). 
To test the hypothesis, telomerase activity and the telomere length have been 
examined in microcell hybrids. Senescence was induced by the reintroduction of 
chromosome 3，but not by chromosome 7 or 11 into a renal cell carcinoma (RCC) 
cell line, which has the short arm of chromosome 3 (Oshimura & Barrett，1997). 
The loss of indefinite growth potential was associated with the loss of telomerase 
activity and shortening of telomeres in the R C C cells containing the introduced 
chromosome 3. Thus, restoration of cellular senescence by chromosome 3 is 
associated with repression of telomerase function in R C C cells and suggest that 
telomerase suppressor is one of several pathways involved in immortalization. 
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In immortal neoplastic keratinocytes, telomerase is found strongly upregulated 
and evidence showed that a telomerase suppressor gene on the short arm of 
chromosome 3 mapping to 3p21.2-p21.3 (Parkinson et al., 1997). However, 
«». 
chromosome 3 did not induce cellular senescence in a telomerase-positive human 
cervical carcinoma cell line (Ohmura et al., 1995). It suggested that not all tumor 
cells might be defective for the same gene controlling telomerase activity. 
Parkinson et al (1997) also mapped the human telomerase R N A gene to 3q26.3 and 
found it to be overrepresented or amplified in a proportion of squamous cell tumors 
and cell lines (Parkinson et al., 1997). So, it is possible that when telomerase 
components themselves upregulated could function as oncogenes. 
L4.11. Telomerase andpl6/pRb Pathway 
The initial growth arrest (mortality stage 0; MO) is apparently controlled by 
1 
the Rb/pl6 pathway because M O can either be prevented by the viral oncoprotein ' 
E7 or reduced pl6 expression. The subsequent M l (mortality stage 1 at which 
normal cell senesces) growth arrest can be bypassed by E6. In some cases, even 
the combination of E6 and E7 still insufficient for immortalization and will enter a 
period of crisis in culture called motality stage 2 (M2). Therefore immortalization 
probably involves inactivation of several pathways. A recent study (Kiyono et al.， 
1998) demonstrated that telomerase activity was not sufficient for immortalization 
ofhuman keratinocyte or mammary epithelial cells: they found that neither addition 
of hTERT nor induction of telomerase activity by E6 resulted in immortalization 
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although both of them were critical for telomere length maintenance. In contrast, 
inactivation ofthe Rb/pl6 pathway by E7 or downregulation of pl6 expression, in 
combination with telomerase activity is able to immortalize epithelial cells 
� 
efficiently. Some other previous studies also demonstrated that loss of pl6 
expression was associated with immortal lines suggesting the role of pl6 in 
immortalization (Vogt et al., 1998; Noble et al., 1996). 
53 
L5. Telomeres and Telomerase Studies in Brain Tumors 
Previous studies on the expression frequency of telomerase activity, telomere 
length and the R N A expression of telomerase R N A component in human brain 
’ . 
tumors are summarized as below: 
/.5.i. Telomerase Activity in Brain Tumors 
Kim et al (1994) not only improved the telomerase activity detection 
method, they also investigated the expression frequencies of telomerase activity in 
different kinds of tumor tissues. It was the first paper analyzing telomerase 
activity in brain tumors. They showed that 6 of 8 brain tumors were telomerase 
positive. Afterwards, many papers specifically focusing on brain tumors were 
published. M y paper on the telomerase activity analysis in human gliomas was 
also published in June 1998 (Chong et al., 1998). 
>' 
Studies of telomerase activity in human brain tumors gave highly variable 
results. An overview of the telomerase expression frequency on some kinds of 
common brain tumors is shown in Table I.4. For the most malignant astrocytic 
tumors G B M , the frequency ranged from 26.3% to 100%. (Langford et al., 1995; 
Nakatani et al.，1997; Sallinen et al” 1997; Morii et al., 1997; DeMasters et al.， 
1997; Chong et al., 1998; Le et al., 1998; Hiraga et al., 1998; Sano et al.，1998; 
Weil et al., 1999). The average expression frequency is about 50 to 70% which is 




































































































































































































































































































































































































































































































































































































































































































1995). For anaplastic astrocytomas and low grade astrocytomas, they have even 
lower detection rates than G B M . Generally, their expression frequencies are 
about 20-40% except those specific cases that only one sample was analyzed in 
、 their study which dramatically increased the frequency to 100%. 
It is interesting to note that oligodendroglial tumors have dramatically high 
expression frequency in most studies including both oligodendrogliomas and 
oligostrocytomas (Langford et al.，1995; Nakatani et al., 1997; Le et al., 1998; 
Hiraga et al., 1998，Morii et al, 1997; Weil et aL, 1999). In some ofthe studies 
which further divided them into categories according to their histopathological 
grade, anaplastic oligodendroglial tumors always show a higher expression 
frequency than in grade II oligodendroglial tumors (DeMasters et al., 1997; Chong 
et al., 1998; Hiraga et aL, 1998). 
The detection rates in other benign brain tumors were very low, or even no | 
j'i 
detectable activity was observed. Pilocytic astrocytomas and pituitary adenomas 
always have no detectable acticvity at all (Morri et al., 1997; DeMasters et al.， 
1997; Chong et al., 1998; Hiraga et aL, 1998, Sano et al., 1998). For 
ependymomas, only our group showed 13.3 % expression frequency in this tumor 
(Chong et al., 1998). 
For meningiomas, activity was usually detected in malignant or atypical 
varaints but seldom in ordinary variants (Nakatani et al., 1997; Langford et al., 
1997; DeMasters et aL, 1997; Hiraga et aL, 1998). On the other hand, high 
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detection rates were found in metastatic brain tumors fNakatani et al., 1997; Sano 
et al., 1998). 
、 /.5.2. Telomere Length in Brain Tumors 
Numberg et al (1993) was the first to study the telomere length alteration in 
brain tumors and about 60% of intracranial brain tumors were found to have 
telomere length alteration when they compared to the peripheral blood leukocytes. 
They were either elongated or reduced in tumors but most of them were elongated 
(41%). On the other hand, there were some evidences showing that telomerase-
positive tumors had a shorter telomere length than telomerase-negative tumors 
(Morii et al., 1997; Hiraga et al., 1998). In contrast to Numberg's study, most of 
the tumors in Hiraga 's study showed length reduction. A summary ofthe 






/.5.5. Telomerase RNA Component Expression in Brain Tumors 
Telomerase R N A was found to be widely expressed in brain tissues. Morii et 
al (1997) found that not only the telomerase-positive gliomas, but also the 
telomerase-negative gliomas and normal brain expressed telomerase RNA. 
Although it was widely expressed, Sallinen et al (1997) and Rushing et al (1997) 
found that telomerase R N A expression level was significantly increased in higher 
grade astrocytomas and ependymomas. Besides, it was also significantly increased 
in tumors that showed increased proliferation activity determined by MIB-1 
immunohistochemistry (Sallinen et al., 1997). 
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Table I.5. An overview of telomere length studies on brain tumors 
Studies Results 
Numberg et al, Among 60 intracranial tumors, 41.7% showed telomere elongation, 21.7% 
1993 telomere reduction and 36.7% exhibited equal length compared with the 
patients' peripheral blood leukoytes 
Morii et aL, telomerase positive gliomas had a mean TRF length < lOkb 
1997 telomerase negative gliomas all had long heterogeneous TRFs which exhibited 
an increased signal peak from 10 to 20 kb 
Hiraga et al, Astrocytic Tumors: 
1998 27/38 (71.1%) telomerase positive tumors displayed reduced TRF length* 
22/30 (73.3%) telomerase negative tumors displayed compatible TRF length 
All PNETs exhibited reduced TRF length 
Neuroepithelial tumors: 
majority (67%) of telomerase positive tumors displayed reduced TRF length 
64.9% of telomerase negative tumors displayed compatible TRF length 
Oligodendroglial tumors: 
4/4 oligodendrogliomas exhibited compatible TRF length 
3/4 anaplastic oligoastrocytomas exhibited reduced TRF length 
3/3 oligoastrocytomas displayed elongated TRF length 
• i 
Benign tumors: 
100% pituitary adenomas, 75% schwannomas, 38.9% meningiomas displayed 
reduced telomere length 





、 This project was started at the end of year 1996, at that time，only a few 
papers showed their telomerase and telomere studies on brain tumors (Kim et al., 
1994; Langford et al., 1995; Nurnberg et al., 1993). Since high telomerase 
detection rate was observed in most of the other tumors and immortal cell lines 
(Kim et al., 1994) and it was likely that telomerase was involved in 
tumorigenesis, we decided to investigate the role of telomerase in our samples. 
Gliomas are the most common brain tumor. Since previous telomerase 
activity studies were done in a small scale, we decided to examine the telomerase 
activity status in human gliomas in a larger scale. Besides the telomerase 
activity, Hastie et al (1990) and de Lange et al (1990) found that tumor samples 
I 
had shorter telomeres than adjacent normal tissue, thus providing the first clue for 
a link between telomeres and cancer. Previous studies showed that telomere 
length alteration was observed in 60% intracranial tumors (Numberg et al., 1993) 
and Morii et al (1997) observed that telomerase-negative gliomas had long 
heterogeneous telomere length when compared to telomerase-positive gliomas. 
As this project was going on, the R N A component of telomerase, telomerase 
reverse transcriptase gene and telomerase associated protein genes were cloned 
and appeared to be involved in telomerase regulation (Feng et al., 1995; 
Nakamura et al., 1997; Harrington et al., 1997). Since previous telomere length 
studies are mainly focused on astrocytic gliomas (Numberg et al., 1993; Morii et 
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al., 1997; Hiraga et al., 1998) and so far there is no hTERT and hTEPl m R N A 
expression analysis on gliomas, the telomere length and the m R N A expression of 
hTERT and hTEPl are further investigated in non-astrocytic gliomas including 
oligodendroglial and ependymal tumors in this study, pl6 and pRb are two 
T 
important cell cycle regulators and probably play a role in cell immortalization. 
Recently, a study (Kiyono et al., 1998) demonstrated that both the pl6/pRb 
inactivation and telomerase activation were required for epithelial cell 
immortalization. Therefore, we also decided to investigate on the relationship 
between telomerase activity status and pl6 or pRb expression in this study. 
In summary, the objectives of my study are: 
0ln order to investigate the role of telomerase in the pathogenesis of different 
grades and subtypes ofbrain tumors, the telomerase activities of diverse 
intracranial brain tumors were examined using a PCR-based TRAP assay in 
this study. 丨 
ii 
；•：'• 
0To measure the telomere length of oligodendroglial and ependymal tumors 
and investigate the relationship between telomere length and telomerase 
activity. 
(Z^To investigate the m R N A expression of telomerase reverse transcriptase 
(hTERT) and telomerase associated protein (hTEPl) in oligodendroglial and 
ependymal tumors and the relationship between m R N A expression of these 2 
subunits and telomerase activity. 
(2^To measure the protein expression of pl6 and pRb in oligodendroglial and 
ependymal tumors by immunohistochemistry and investigate the relationship 
between expression and telomerase activity. 
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III.1. Telomerase Activity Study  
IIL1.1. Specimens 
One hundred and thirty-one snap-frozen tumors, including 16 pilocytic 
astrocytomas, one dysembryoplastic neuroepithelial tumor (DNT), two 
pleomorphic xanthoastrocytomas (PXA), 19 ependymal tumors, 23 
oligodendrogliomas (11 grade II and 12 anaplastic), 6 oligoastrocytomas (4 grade II 
and 2 anaplastic), 13 grade II astrocytomas, 13 anaplastic astrocytomas and 38 
glioblastoma multiforme tumors (GBM) were included in this study. They were 
mostly collected from the Prince of Wales Hospital, Hong Kong (n= 110). The 
！ 
Others were collected from hospitals in mainland China. These hospitals include 丨: 
Anhui Provincial Hospital, Hefei (n=8), Beijing Hospital, Beijing (n=6), Rui Jin 
Hospital, Shanghai (n=3), Sir Run Run Shaw Hospital, Hangzhou (n=3) and West 
China University of Medical Sciences, Chengdu (n=l). Normal brain tissue was 
removed from patient. All tissues were confirmed histologically to be diagnostic 
tissues. All tumors were classified and graded according to the World Health 
Organization (WHO) (Kleihues et al., 1993) and fresh tissues were stored at -
80¾ until analysis. W H O criteria for tumor grading was introduced in Section 
L1. The clinical data of these tumor samples is summarized in Table III.1. 
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Table III.1. The clinical data of the tumor samples in telomerase activity study 
Tumors No. of Age range (years) Mean age Male to 
‘ cases (years) Female ratio 
Pilocytic astrocytomas 16 2-35 13.9 11:5 
Dysembryoplastic 1 21 21 0:1 
neuroepithelial tumors 
Pleomorphic 2 27-39 33 2:0 
xanthoastrocytomas 
Ependymal tumors 19 1-60 25.4 8:11 
ependymomas 18 1-60 25.3 7:11 
anaplastic ependymomas 1 27 27 1:0 
Oligodendrogliomas 23 14-78 44.2 16:7 
Grade II 11 14-78 37.4 7:4 
Anaplastic 12 26-70 50.5 9:3 
Oligoastrocytomas 6 7-51 39.8 2:4 
Grade II 4 7-50 35.5 2:2 
Anaplastic 2 46-51 48.5 0:2 
Grade II astrocytomas 13 7 months-66 37.3 5:8 
Anaplastic astrocytomas 13 8-72 37.4 7:6 i 
) I 
ii 
G B M 38 17-76 51.5 22:16 
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IIL1.2. TelomeraseExtraction 
Since telomerase is an enzyme, the handling to telomerase is the same as 
%. 
protein sample handling. The C H A P S lysis buffer for telomerase extraction was 
provided in the TRAP-eze telomerase detection kit (Oncor, Inc., Gaithersburg, 
MD). 
Frozen tissue was washed in IX phosphate-buffered saline (PBS), 
homogenized, and lysed in 20 to 100 ^il C H A P S lysis buffer (lOmmol/L Tris-HCl, 
pH 7.5, lmmol/L MgCl2, 1 mmolyl. ethylene glycol tetra-acetic acid (EGTA), 0.1 
mmol/L Benzamidine, 5 mmol/L fi-mercaptoethanol, 0.5% CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-l -propanesulfonate), 10% glycerol) | 
;i 
depending on the size of tumor sample. After incubation for 30 minutes on ice, the 
lysate was centrifUged at 13000 rpm for 30 minutes and the supernatant was 
••'i 
'••V 0 ‘ 
collected and stored at -80 C. 彳 
IIL1.3. Protein Concentration Measurement 
Telomerase concentration was determined by Bio-Rad D C Protein Assay 
according to the manufacturer's instruction (Bio-Rad laboratories, Hercules, CA). 
For each five ^ 1 of the protein extract, it was mixed with 125 ^ il of reagent A (an 
alkaline copper tartrate solution) with reagent S inside (20^ il reagent S per 1ml 
reagent A) and 1 ml of reagent B (a dilute Folin Reagent). The absorbance of the 
63 
mixture was then measured at 750 nm using UV-spectrophotometer (Beckman 
Instruments, Inc., Fullerton, CA) after votex and incubation at room temperature 
for 15 minutes. The protein concentration was read from a standard curve. The 
* 
standard curve was prepared by measuring the absorbance ofO, 1, 3，5, 7，9 mgAnl 
bovine serum albumin (BSA). An aliquot of the extract containing 1 ^ig protein 
was used for each TRAP assay. In addition, 1:10 and 1:100 diluted protein 
extracts were also examined to reduce the possibility of the presence of Taq 
inhibitors. 
III.1.4. RNase- treatedSamples 
For RNase-treated sample, lysate with RNase was incubated at 37^C for 20 
minutes before the TRAP assay. 
IILL5. TRAPAssay 
TRAP assay was developed by Kim et al in 1994. It is the most commonly 
used method to detect telomerase activity in tissues and cells nowadays. The 
principle of TRAP assay was described in Section 1.4.7.1 in details. A 
commercial detection kit, TRAP-eze telomerase detection kit (Oncor), was used in 
this study. The methodology utilized in the TRAP-eze kit is based on an improved 
version of the original method described by Kim et al (1994). The TRAP-eze kit 
is a highly sensitive in vitro assay system for detecting telomerase activity. The 
assay is a one buffer, two enzyme system utilizing the polymearse chain reaction 
64 
(PCR). In the first step of the reaction, telomerase adds a number of telomeric 
repeats onto the 3'end of a substrate oligonucleotide. In the second step, the 
extended products are amplified by the PCR using the TS and RP (reverse) primers, 
n . 
generating a ladder of products with 6 base increments starting at 50 nucleotides: 
50, 56，62，68，etc. 
The TRAP-eze telomerase detection kit provides substantial improvements to 
the original TRAP assay, such as a modified reverse primer sequence which 
eliminates the need for a wax barrie hot start, reduces amplification artifacts and 
permits better estimation of telomerase processivity. 
IILl.5.1. TS Primer Labelling 
I 
For each PCR reaction, 0.25^ il of TS primer 
(5'AATCCGTCGAGCAGAGTT3') was 5'-end labeled with 0.5jiCi of [y^ P^] :¾ 
, i 
adenosine triphosphate (ATP) (5,000 Ci/mmole, Amersham, Buckinghamshire, 
U K ) and 0.3 units of T4-polynucleotide kinase (PNK) (Amersham) in IX P N K 
buffer to make a total reaction volume of 0.5^ il. The reaction mixture was 
incubated at 37^C for 45 minutes and then 6 5 ¾ for 5 minutes. 
III.1.5.2. TS Primer Extension And PCR Amplification 
The TRAP assay was performed in a 12.5 ^il reaction mixture containing 0.5 
i^l enzyme extract, 0.05 mmol/L deoxynucleoside triphosphate (dNTP), IX TRAP 
65 
buffer (20 mmol/L Tris-HCl, pH 8.3, 1.5 mmol/L MgCl2, 63 mmol/L KC1, 0.05 % 
Tween 20，1 mmol/L EGTA, 0.01 % BSA), 0.5^1 of labelled TS primer product, 
0.25 ^ 1 of primer mix (including control template, reverse primer, and the primer 
V 
for generating a 36-bp fragment) which was provided in the kit and 0.5 unit of Taq 
D N A polymerase (Perkin Elmer, Norwalk, CT). After a 20-minutes' incubation at 
3 0 ¾ in the thermocycler block to allow telomerase-mediated extension of TS 
primer, 30 cycles ofPCR reaction was performed at 94^C for 30 seconds, 58^C for 
30 seconds, and 72^C for 30 seconds. The reaction was ended with extension at 
r f C for 10 minutes. 
IIL1.6. Non-Denaturing Polyacrylamide Gel Electrophoresis 
I 
I 
Five microliters of stop buffer (95% formamide, 10 m M E D T A (pH 8.0)， 
0.05% bromophenol blue, 0.05% xylene cyanole) containing bromophenol blue and 
xylene cyanole was added to the PCR product. Two microlitres aliquot of the PCR ‘ 
product was then separated on a 12.5 % nondenaturing polyacrylamide gel (with 
40% acrylamide, 2 % bis-acrylamide) in IX TBE buffer (0.5 M Tris, 0.5 M boric 
acid, 0.025 M EDTA). The gel was run under constant voltage, 1200 volts for 2-3 
hours at room temperature. The gel was vacuum dried and exposed to a Kodak X-
O M A T A R film (Eastman Kodak Company, Rochester, N Y , USA) at -80^C 
overnight. 
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IILL 7. Data Analysis 
Telomerase activity was determined positive if a 6-bp laddering pattem was 
、 observed. The laddering pattern was due to the "temporary break" of telomerase 
after synthesis of each set of six nucleotides. Conversely, the appearance of an 
amplified internal standard 36-bp fragment but not the 6-bp ladder was considered 
as activity negative. In this study, the RNase-treated sample was used as a 
j 
negative control. When the lysate was incubated with RNase, the R N A template 
would be destroyed by RNase; thus, no 6-bp ladder could be observed. The 
positive control was provided in the kit as a comparison with other samples. 
Besides, the reagent control containing only lysis buffer instead of protein extract 
was included to monitor possible contamination. All positive cases were repeated 
I 




IILL8, Statistical Analysis ； 
For each tumor type, the mean age difference between telomerase-positive 
and telomerase-negative was assessed by two-tailed Student's t-test, with Microsoft 
Excel software programe (Microsoft Corp, Redmond, WA). The statistical 
difference between the telomerase expression frequency of grade II and grade III 
oligodendroglial tumors was accessed by Microsoft Excel Chi-test (Microsoft 
Corp). 
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III.2. Telomere Length Study  
IIL2J, Specimens 
1 
This part of study focused on the oligodendroglial and ependymal tumors. 
Thirty seven snap frozen tumors, including 23 oligodendroglial tumors with 18 
oligodendrogliomas (9 grade II and 9 anaplstic) and 5 oligoastrocytomas (3 grade II 
and 2 anaplastic), and 14 ependymal tumors were collected from the Prince of 
Wales Hospital, Hong Kong (n=30), Anhui Provincial Hospital, Hefei (n= 4), 
I 
Beijing Hospital, Beijing (n=l), Sir Run Run Shaw Hospital, Hangzhou (n=l) and | 
j 
I ； 
West China University of Medical Sciences, Chengdu (n=l). All tumors were 
classified and graded according to the World Health Organization (WHO) i 
i 
(Kleihues et al., 1993) and fresh tissues were stored at -80^C until analysis. All ;| 
tumor samples in this study were included in telomerase activity study as described 






Table III.2. The clinical data of tumor samples in telomere length study 
Tumors No. of Age range Mean age Male to 
� cases (years) (years) Female ratio 
Oligodendroglial 
Tumors 
Oligodendrogliomas 18 14-78 45.9 11:7 
Grade II 9 14-78 38.1 5:4 
Anaplastic 9 39-70 53.7 6:3 
. 1 
Oligoastrocytomas 5 7-51 39.2 2:3 
Grade II 3 7-50 33 2:1 
Anaplastic 2 46-51 48.5 0:2 ,! !• •j 
i 
Ependymal Tumors 14 3-60 26.4 6:8 \ 
I 
1： 
Ependymomas 13 3-60 26.3 5:8 j 





•\' .,i V 
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III.2.2. DNA Extraction 
Genomic D N A was extracted from frozen tissue samples according to the 
standard phenol/chloroform protocol (Sambrook et al., 1989). The cell membrane 
and proteins was lysed and denatured in the first step. D N A was then extracted by 
phenol/chloroform and finally was precipitated to remove salts and small organic 
molecules. The protocol is described as follow: 】 
i 
i 
Snap frozen tissue was washed in IX PBS, homogenized and digested in 4 ml 
ofextraction buffer containing 3.8 ml STE (O.lM NaCl, 0.05M Tris, pH 7.5, l m M 
EDTA, pH 7.4), 0.2 ml oflO% (w/v) sodium dodecyl sulfate (SDS) and 40 ^il of 10 
mg/ml proteinase K at 55。C overnight. Equal volume (4ml) of j ： 
. i i 
phenol/chloroform/isoamy alcohol (25:24:1 in volume, pH 8.0) (Amersco, Solon, J 
I 
n I 
Ohio) was added, mixed vigorously, placed at -80 C for 10 minutes and then 
I ； ' f 
centrifuged at 4000 rpm for 20 minutes. The upper layer was collected and mixed J 
with 2X volume (8ml) of 100% ethanol and O.lX volume (0.4 ml) of sodium 
acetate O^aAc). The mixture was stored at -80^C for at least 1 hour. After 
centrifugation at 4000 rpm for 20 minutes, the supernatant was removed and the 
pellet was washed in 70 % ethanol twice and 100 % ethanol once. The pellet was 
dried under vacuum, dissolved in MilliQ water and stored at -80¾ until analysis. 
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IIL2,3. DNA Concentration Measurement 
One |il of D N A was diluted in 1 ml of distilled water and the absorbance was 
， measured at 260 nm and 280 nm using UV-spectrophotometer (Beckman 
Instruments, Inc., Fullerton, CA). The formula used was listed below: 
D N A in ^ig/ml = (abs (260)nm *50 + abs (280)nm *0) * dilution factor , 
,! 
The integrity o f D N A was confirmed by running a 1 % agarose gel (0.5g agarose in 丨 
50 ml IX TBE buffer) using 1 ^ig ofDNA. 
IIL2.4. Analysis of Telomere Length by Southern Hybridization 
\ 
1 
Localization of particular sequences with genomic D N A is usually 丨 
accomplished by the transfer techniques described by Southern in 1975 (Sambrook 
！ 
et al., 1989). Genomic D N A is first digested with one or more restriction ！ 
V 
enzymes, separated by electrophoresis through an agarose gel. The D N A is then 
denatured and transferred from the gel to a solid support, usually a nitrocellulose 
sheet. The positions of the D N A fragments in the gel are preserved in the 
nitrocellulose sheet where they can be hybridized with a ^ P^-labeled single-stranded 
D N A probe. Autoradiography then reveals the position of the restriction fragment 
with a sequence complementary to that of the probe. A schematic diagram of 





























































































































































































































































































111.2.4.1. DNA Digestion 
One i^g of integrated D N A sample was digested with 7.5 units of restriction 
， enzyme, HinfL (Amersham) in IX high salt buffer (50 m M Tris-HCl, pH 7.5, 10 
m M MgCl2, 1 m M dithiothreitol, 100 m M NaCl) at 37^C for 2 hours. After that, 
the digested sample was separated by electrophoresis on 0.8% agarose gel. The 
gel was run at 20 volts ovemight, afterwards, gel was stained with ethidium 
,1 
bromide (EtBr) and the completeness of digestion was checked under U V light. A 
transparent ruler was placed alongside the gel so that the distance of any D N A band 
!• 
I 
had migrated can be read directly from the photographic image. The cutting site of 
暴 





111.2.4.2. Southern Blotting , 
The EtBr stained gel was washed in distilled water for 15 minutes, : 
I ‘ 
';.； 
depurinated in 0.25N HC1 for 15 minutes, denaturated in 0.5M NaOH/1.5M NaCl ; 
for 30 minutes and finally neutralized in lM Tris, pH 8.0/1.5M NaCl for another 30 
minutes, with gentle and constant agitation at room temperature all the time. Any 
unused areas of the gel were trimmed with razor blade. A piece of Whatman 3 M M 
paper (Springfield Mill, England) was wrapped around a gel tray to form a support 
that was longer and wider than the gel when the gel was in the neutralization 
solution. The wrapped support was placed inside a container which was filled with 
transfer buffer, 10X SSC (3M NaCl, 0.3M sodium citrate), until the level ofthe 
liquid reached almost the top of the support. Any air bubbles on the top of the 
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3 M M paper was smoothed out with a glass rod to prevent short current. A 
Hybond N + membrane (Amersham) that was closely fit the gel was prepared and 
wet with deionized water and transfer buffer. The gel was removed from the 
� . 
neutralization solution and was placed on the support. Any air bubbles between 
the gel and 3 M M paper was smoothed out. The gel was then surrounded by Saran 
Wrap and the wet membrane was placed on top of the gel. Again, any air bubbles 
between the gel and the membrane should be smoothed out. Two pieces of 3 M M 」: 




absorbant pads and a weight were placed on top of them to weigh it down. This 
set up a flow of liquid from the buffer through the gel and the membrane, so that 
the denatured D N A was eluted from the gel and was deposited on the membrane. 
I 
The transfer of D N A was allowed to proceed for 17-24 hours. The whole set up | 
I 
was illustrated in Fig. IIL2. 
I 
I I 
Ten pmol of telomeric probe (TTAGGG)4 was 5'-end labelled with 3.5 ^ Ci y- j 
32 
P-ATP (Amersham) using 0.3 units of T4 polynucleotide kinase (Amersham) at 
37^C for 30 minutes. The reaction was stopped by adding 5 ^ 1 of 0.5M EDTA, pH 
8.0. The membrane with D N A deposited was taken out and the gel direction was 
labeled with a mark. The gel was stained with EtBr to check for the completeness 
of transfer. The membrane was rinsed with 2X SSC for 15 minutes and fixed in 
N a O H for 20 minutes. Afterwards, the membrane was rinsed with 2X SSC three 
more times for 15 seconds each. After drying, it was cross-linked by using the U V 
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Fig. III.2. Capillary transfer o f D N A from agarose gel. Buffer is drawn from a 
reservoir and passes through the gel into a stack of absorbant pads. The D N A is 
eluted from the gel by the moving stream ofbuffer and is deposited on a 
nitrocellulose filter or nylon membrane. A weight applied to the top of the 
absorbant pads helps to ensure a tight connection between the layers of material 
used in the transfer system. 
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The membrane was wet with 6X SSC, slipped into a hybridization bottle and 
prehybridized in 15 ml Rapid-Hyb buffer (Amersham) at 50¾ for 30 mins. At the 
^. 
same time, the radiolabeled probe was eluted through a ProbeQuant G-50 micro 
columns (Pharmacia Biotech, USA). The elute was collected by spinning at 6500 
rpm for 30 seconds. The purified probe was then added to the prehybridization 
solution and the membrane was left to be hybridized by the labelled probe for ： 
another 2 hours at 50^C. After hybridization, the membrane was washed in 2X SSC 
/0.1% SDS two times and one time in IX SSC/0.1% SDS at 42^C for 10 mins each. 
I； j 
The damp membrane was placed on a 3 M M paper and wrapped with Saran Wrap. 
Autoradiography was performed using Kodak X - O M A T A R film (Eastman Kodak 
i 
Company) at -80^C overnight. | 
I 
///.2.5. Data Analysis 
；>' 
V 
The intensity ofhybridization signals was scanned and analyzed by the Fluor-
TIvl 
S MultiImager (Bio-Rad Laboratories, Hercules, CA). The terminal restriction 
fragments (TRFs) were estimated as indicators of mean telomere length at the peak 
position of the hybridization signals. A D N A size marker with known base pairs 
fragments was included for each gel. It was used as a standard and the logarithm 
of D N A mass in base pairs versus the distance travelled of each fragment in the gel 
was plotted as a standard graph. The mean telomere length expressed in kb was 
read from the standard graph. 
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IIL2,6, Statistical Analysis 
‘ For each tumor type, the mean age difference and the mean TRF length 
difference between telomerase-positive and telomerase-negative groups were 
assessed by two-tailed Student's t-test，with Microsoft Excel software programe 
(Microsoft Corp). 
’丨 












lII3. hTERT and hTEPl mRNA Expression Study  
IIL3.1. Specimens 
This part of the study focused on the oligodendroglial and ependymal tumors. 
Twenty-six snap frozen tissues, including 14 oligodendroglial tumors with 10 
i 
oligodendrogliomas (3 grade II and 7 anaplastic) and 4 oligoastrocytomas (3 grade 
II and 1 anaplastic), and 12 ependymal tumors were analyzed in this study. They j 
were included in telomerase activity study as described in section III.1.1 and some 
of them were included in telomere length study. Twenty-two samples were i 
• I 
obtained from Prince of Wales Hospital, Hong Kong. The others were from Anhui i 
i 
Provincial Hospital, Hefei (n=2), Beijing Hospital, Beijing (n=l) and West China | 
University of Medical Sciences, Chengdu (n=l). The clinical data of these tumor 
samples is summarized in Table III.3. 
.>' 
V 
IIL3.2. RNA Extraction and DNase Treatment 
Snap frozen tissue was cut into small pieces with razor blade in the presence 
of 1ml Trizol reagent (Life Technologies) on a tissue-culture plate. It was further 
homogenized using a homogenizer. The mixture was added to 0.2 ml of 
chloroform, vigorously shaked and centrifuged at 13000 rpm for 15 minutes at 4 ¾ . 
After centrifugation, the upper aqueous layer was collected, then mixed with 0.5 ml 
isopropanol and incubated at room temperature for 10 minutes. R N A pellet was 
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Table III.3. The clinical data of tumor samples in mRNA expression study 
， - •丨丨 I ‘ ‘ - . - , - 1 . , . . 1 • 丨 丨 ， 1 1 1 •• 
Tumors No. of Age range Mean age MaIe t© 
cases (years) (years) Femaie ratio 
Oligodendroglial 
Tumors 
Oligodendrogliomas 10 16-70 51.0 6:4 
Grade II 3 16-35 26.7 2:2 ^ 
Anaplastic 7 39-70 56.1 4:3 
Oligoastrocytomas 4 42-46 45.3 1:3 ； 
Grade II 3 42-50 45 1:2 ,| 
Anaplastic 1 46 46 0:1 
'i '! 
Ependymal Tumors 12 3-60 26.2 5:7 
• 
Ependymomas 11 3-60 26.1 4:7 i| 









obtained by centrifugation at 12000 rpm for 10 minutes at 4^C. The pellet was 
washed in 70% ethanol. 
1 
The air-dried, ethanol-precipitated R N A pellet was dissolved in the DEPC 
water and incubated in IX DNase I buffer (Life Technologies) and digested with 5 
units of DNase I (Life Technologies) in a total volume of 50 ^ il for 15 minutes at 
room temperature. The reaction was stopped by adding 2.5 m M E D T A and heated \ 
at 6 5 ¾ for 10 minutes. This DNase treatment removed the contaminated D N A 
during extraction that would affect the later PCR reaction. Afterwards, the R N A 
was extracted by equal volume (50 ^ il) of phenol/chloroform. The mixture was .； 
mixed and added to the phase-lock gel. After spinning down, the upper aqueous 
I 
layer was collected. 2X volume (lOO^ il) of 100% ethanol and 1/10 volume (5 ^il) | 
I 
of 3 M NaAc was added. The mixture was stored at -20^C until analysis. 
V 
x' 
IIL3.3. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
RT-PCR is a two-step process. The first step is a reverse transcription step. 
R N A is the template for the synthesis of a complementary D N A (cDNA) strand by 
an enzyme, reverse transcriptase, an RNA-directed D N A polymerase. In this 
case, genetic information flows from R N A to D N A , the reverse of the normal 
transcription. Actually, a number of R N A viruses produce malignant tumors after 
being injected into susceptible animal host by use of reverse transcription 
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A 
mechanism. Experimentally, many studies are based on this mechanism to 
investigate the R N A expression of a gene. The second step involved is PCR 
amplification of c D N A product from the first step. It is the regular P C R reaction 
n . 
to increase the amount of c D N A copies for observation. 
II.3.3.1. Primer Design 
,,i 
The primers selected for RT-PCR reaction usually span across 2 or more 
exons. Since D N A cannot be totally removed by DNase in some cases, this 
I 
strategy is applied in order to distinguish the amplified P C R product from genomic ; t 1 
1； 
D N A and c D N A template. The strategy is illustrated in Fig. III.3. In this study, 丨 
m R N A expression of hTERT and hTEPl were studied and P-actin was used as an i 
•| 
I 
internal control to check for the quality of R N A . All the primers chosen were i 
m R N A specific. The primer sequences and their c D N A fragment sizes are listed 
in Table III.4. 
.i' 
IIL3.3.2. Standard Protocol 
Before use, the DNase treated R N A stored in EtOH was spinned down, 
washed in 70% EtOH, air-dried and dissolved in DEPC water. Six microlitres of 
R N A was annealed with 5^ ig random hexamers (Pharmacia Biotech) and reversed 
transcribed in IX RT Buffer (Life Technologies), 0.01M DTT, 0.5mM dNTP and 
200 units of M - M L V Reverse Transcriptase (Life Technologies). The reaction 
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A. using primers span across 3 exons 
Genomic D N A template 
， 
^ E3 P C R product from genomic D N A 
" • “ • • _ • 
El 11 E2 12 < 
i| 
cDNAtemplate Different P C R product 
from c D N A 
> E3 
——• 
El E2 • 
卜 
；！ 




Genomic D N A template PCR product from 
^ 11 E2 12 E3 genomicDNA 丨 
• • “ ^ — — 
< 
cDNAtemplate SamePCR^oduct 
_. ^ from c D N A 
:1 E2 E3 
< 
Fig. in.3. Two strategies of primer design. A. primers spanning across 
2 or more exons give different PCR products from genomic D N A and 
c D N A because introns are absent on cDNA. B. primers on the same exon 
give indistinguishable product. El, E2, E3, II，12 are exonl, exon2, exon3 
intronl and intron 2 respectively. 
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Table III.4. Primer Sequences for hTERT, hTEPl and P-actin 
Name Annealing cDNA Sequences 
> Temperature .^^ ^ 
hTERT 
TRT7U1426 * 58¾ 282 bp 5'-CCTCTGTGCTGGGCCTGGACGATA-3' 




TLPim4792 * 60¾ 334 bp 5'-CTTGGAATTGGGTCTGGTCTCTCG-3' ] 
TLPl/L5102 * 5'-CACAGCAGTAGGGGATGAGGAAAC-3' 
P-actin 
p-actinFl# 540c 626 bp 5'-CCTCGCCTTTGCCGATCC-3' ！ 
p-actin R1^ 5'-GGATCTTCATGAGGTAGTCAGTC-3' j 
*These primers have been described previously by Nakayama et al (1998). i 







mixture was incubated at 42®C for 1 hour and then inactivated at 90^C for 4 
minutes. 
«», 
Following RT, the cDNA was amplified by PCR. The reaction volume was 
20yd in total, including l^ il ofRT product as template with 2.5mM Mg�+，0.2mM 
dNTP, 0.6^M primers (see Table IIL4) and 0.35 units Taq Gold D N A Polymerase 
(Perkin Elmer). The amplification was performed in a Thermal Cycler with an ； 




60s annealing at 54-60 ^ C and 60s elongation at 72 ^ C, then followed by 38 cycles 
for 30s denaturing at 94®C, 30s annealing at 54-60¾ and 50s elongation at 72^C. 
Specific annealing temperature for each pair of primers is listed in Table III.4. ^ 
The PCR product was then resolved on 1% agarose gel, stained with ethidium | 
I 
bromide and examined under U V light. A hTERT and hTEP 1 positively expressed 
i 




IIL3.4, Statistical Analysis 
For each tumor type, the mean age difference and the expression frequencies 
difference between telomerase-positive and telomerase-negative groups were 
assessed by two-tailed Student's t-test and Chi-test respectively, with Microsoft 
Excel software programe (Microsoft Corp). 
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111.4. pl6 and pRb Immunostaining  
IIL4.L Specimens 
»». 
This part of the study also focused on the oligodendroglial and ependymal 
tumors. Paraffin blocks from 22 oligodendroglial tumors with 16 
oligodendrogliomas (8 grade II and 8 anaplastic) and 6 oligoastrocytomas (4 grade \ 




pathology files of Prince of Wales Hospital, Hong Kong. They were included in 
telomerase activity study as described in section IIL1.1 and some of them were 
included in telomere length and m R N A expression study. All tumors were 
I 
classified and graded according to the World Health Organization (WHO) | 
I 
(Kleihues et al., 1993). All tissues had been fixed in 10% buffered neutral 
formalin for periods varying from 4 to 24 hours and routinely processed between 
I 
i 
1987 and 1998. The clinical data of these tumor samples is summarized in Table , 
111.5. 
IIL4.2. Slide Preparation 
Slides stained with haematoxylin and eosin were reviewed and representative 
blocks were selected. Four micro-meter thick sections were further cut from 
representative blocks. Each section mounted on a 2 % 3-Aminopropyltri-
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Table III.5. The clinical data of tumor samples in pl6 and pRb protein expression 
Tumors No. of Age range Mean age Male to 
‘ cases (years) (years) Female ratio 
Oligodendroglial Tumors 
Oligodendrogliomas 16 29-78 50.4 12:4 
Grade II 8 29-78 44 6:2 
Anaplastic 8 39-70 56.9 6:2 
Oligoastrocytomas 6 7-51 39.8 2:4 ； 
Grade II 4 7-50 35.5 2:2 
Anaplastic 2 46-51 48.5 0:2 
i f 
. .1 
Ependymal Tumors 15 3-60 28.7 6:9 
Ependymomas 14 3-60 28.9 5:9 丨 













The method used to examine the protein expression of pl6 or pRb in this 
study was avidin-biotin complex (ABC) method. Avidin is a large glycoprotein 
extracted from egg white (albumen) and has four binding sites per molecule for 
biotin. Biotin is a vitamin in several tissues, has one binding site for avidin and 
can be attached to an antibody or other macromolecule through other site. In this 
• i 
method, the second antibody is biotinylated and the third reagent is a complex of 
ij 
avidin mixed with biotin that has been labeled with an appropriate marker. The ,| 
protocol is described as below. ‘ 
:i 
Paraffin sections were dewaxed by passing through xylene three times and : 
absolute alcohol twice. Sections were further rehydrated in a series of graded 
alcohols and rinsed well with distilled water. Antigen was retrieved by microwave 
at 37V for 20 minutes. Endogeneous peroxidase was blocked with 3% aqueous 
H2O2 for 5 minutes because peroxidase is presented in peroxisomes and may be 
found in macrophages. Suppression of the activity of this enzyme must be carried 
out before application of the peroxidase-linked reagent. Afterwards, the section 
was rinsed with Tris buffered saline (TBS; 0.05M, pH 7.6). The slide was blocked 
with 5% normal rabbit serum. Primary pl6 monoclonal antibody (1:500; 
87 
A 
Pharmingen, San Diego, USA) or Rb monoclonal antibody (1:100; Pharmingen) 
was then applied on individual section and incubated ovemight at room 
temperature. After washing in TBS buffer three times for 10 minutes each, the 
«» 
secondary biotinylated rabbit anti-mouse antibody (1:200; Dako, Glostrup, 
Denmark) was applied for 45 minutes. Slides were then washed in TBS buffer and 
treated with the avidin-biotinylated peroxidase complex (1:100; Dako) for 1 hour. 
Again, slides were washed in TBS buffer, developed in 3,3-diaminobenzidine 
tetrahydrochloride (Dako) and counterstained with Mayer haematoxylin. 
i 
I 
Diaminebenzidine would react with peroxidase to form oxidized diaminebenzidine '丨 
1 




IIL 4.4. Data Analysis \ 
i 
For pl6 expression, tumors with more than 10% positive nuclei per high 丨 
power field were considered positive and defined as no pl6 alteration fKakamura et ! 
1 ‘ 
al., 1996). A tumor with an altered pRb expression was defined when a tumor 
with no nuclear staining of tumor cells in each of the fields in contrast to positively 
stained endothelial cells in the same area. Tumors were defined as nonevaluable 
for staining for pRb if there was no pRb staining in the tumor cells and no 
concomitant staining of the surrounding endothelial cells (Jahnson et al., 1998). 
Sections of glioblastoma previously determined to express pl6 or pRb were also 
included as positive control. 
88 
A 
IIL4.5. Statistical Analysis 
For each tumor type, the mean age difference and the expression frequencies 
‘ difference between telomerase-positive and telomerase-negative groups were 
assessed by two-tailed Student's t-test and Chi-test respectively, with Microsoft 
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IV.1. Telomerase Activity Study  
Totally one hundred and thirty-one brain tumors were included in telomerase 
activity study. They were 16 pilocytic astrocytomas, 1 DNT, 2 PXA, 19 
ependymal tumors, 23 oligodendrogliomas, 6 oligoastrocytomas, 13 grade II 
astrocytomas, 13 anaplastic astrocytomas and 38 G B M . As described in Section 
！ 
III.1.7, the appearance of a six-base pairs laddering pattem was considered as 
telomerase positive. On the other hand, the appearance of internal control but not 
the laddering pattern was considered as telomerase negative. The laddering pattern 
was demonstrated in Fig. IV.1 and Fig. IV.2. The results of telomerase activity 
expression on these tumor samples were summarized in Table IV.1. 
. t 
(‘ 
In this study, none of the pilocytic astrocytoma (n=16), D N T (n=l) and PXA 
(n=2) had detectable activity. For ependymal tumors, no activity was detected in 
myxopapillary variant (n-=2), subependymoma (n=l) and anaplastic ependymoma 
(n=l). On the other hand, two of fifteen (13.3%) classical ependymomas were 
detected as telomerase positive. Both of the telomerase-positive patients were 
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Fig. IV.1. Telomerase activity in glioblastomas. Lane 1, normal brain 
tissue; Lane 3, positive control; Lanes 5, 7, 9, 11, Four representative 
telomeras-positive G B M samples in original 1 \xg/\iL concentration. 
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Fig. IV.2. Telomerase activity in non-astrocytic gliomas. A. Ependymoma 
(case 91S10628). B. Oligodendroglioma (case 97S14327). Six basepair 




























































































































































































































































































































































































































































































































Ten out of23 (43.5%) oligodendrogliomas had detectable enzyme activity. Of 
these, 3 out of 11 (27.3%) grade II oligodendrogliomas and 7 out of 12 (58.3%) 
anaplastic oligodendrogliomas were telomerase positive. The age range of 
>. 
oligodendrogliomas analyzed was between 14 to 78 years. The mean age of 
telomerase-positive patients were 48.1 years while the mean age of telomerse-
negative patients were 41.2 years (P=0.35, student's t-test). For the 12 anaplastic 
tumors, the mean age of telomerase-positive and telomerase-negative patients were 
52.3 and 48 years old respectively (P=0.65, student's t-test). Of these 23 
oligodendrogliomas, four of them were recurrent tumors and all were telomerase 
positive. Eight of ten telomerase-positive oligodendrogliomas were located at 
- I 
frontal lobe and 7 telomerase-positive patients were male. Two of six 
oligoastrocytomas (33.3%) showed telomerase activity. One telomerase-positive 
tumor was grade II and the other was anaplastic. 
！ 
The telomerase expression frequency in 13 grade II astrocytomas and 13 
anaplastic astrocytoma was the same, i.e. 23.1%. The mean age of telomerase-
positive grade II astrocytoma group was 48 years which was significantly higher 
than the mean age of telomerase-negative grade II astrocytomas group (34.1 years, 
P= 0.05, student's t-test). The three telomerase-positive patients were female. 
These tumors were from frontal lobe, parietal lobe and corpus callosum. On the 
other hand, the mean age of patients with telomerase-positive anaplastic 
astrocytoma were 35.3 years while telomerase-negative patients was 38 years 
94 
A 
(P=0.882, student's t-test). Two telomerase-positive patients were female and these 
telomerase-positive tumors were from occipital lobe, brain stem and parietal lobe. 
>. 
Ten of thirty-eight G B M (26.3%) were detected as telomerase positive. 
Seven of the ten telomerase-positive patients were female. Of these ten 
telomerase-positive tumors, 4 were from frontal lobe, 3 from temporal lobe, 2 from 
parietal lobe and 1 from corpus callosum. The mean age of positive patients was 
61.7 years while the mean age of negative patients was 47.8 years (P=0.002, 
student'st-test). Telomerase activity was also investigated in normal brain tissue 





IV.2. Telomere Length Study  
The telomere length of 23 oligodendroglial tumors (18 oligodendrogliomas 
^. 
and 5 oligoastrocytomas) and 14 ependymal tumors were measured so as to 
investigate the relationship between telomere length and telomerase activity in non-
astrocytic gliomas when sufficient materials were available. Fig.IV.3 illustrates 
TRFs in some representative cases. The TRFs appear as a smear on a gel because 
both the size of the subtelomeric region and the number of T T A G G G repeats vary 
on different chromosomes, and the mean TRF length varies between cells within a 
population (Rogan et al., 1995). The highest signal peak from the film was 
measured and the size of this specific peak in kilobases was taken as the TRF of 
each sample. The clinical and TRF length data of samples analyzed are shown in 
Table IV.2. A summary of mean TRF length of these samples is listed in Table 
IV.3. 
Oligodendroglial Tumors 
For oligodendroglial tumors, the mean TRF length of telomerase-positive 
tumors (n=9) was 11.50 kb which was ranged from 6.6 kb to 21.6 kb. One of them 
had a length greater than 20 kb, 4 cases ranged between 10-20 kb and 4 cases were 
less than 10 kb. The mean TRF length of telomerase-negative tumors was 13.05 
kb with a range from 7.4 kb to 18.6 kb. Most of the telomerase-negative tumors 
showed a length between 10-20 kb (n=l 1) while the rest (n=3) were less than 10 kb. 
96 
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Fig. IV.3. Telomere length analysis in oligodendroglial and ependymal 
tumors. Lane 1, 2: telomerase-negative (tel -) oligodendrogliomas. Lane 
3, 4: telomerase-positive (tel +) oligodendrogliomas. Lane 5; 
telomerase-negative ependymoma. Lane 6, 7: telomerase-positive 




Table IV.2. The clinical data and TRF length measured on oligodendroglial 
and ependymal tumors 
case surgical no tumor sex age site TRF TeI act  
subtype length (kb)  
Oligodendroglial Tumors 
*. 
1 88S216 0 M 67 left occipital 15.5 -
2 88S3489 0 F 78 right temporal 15.7 -
3 88S5759 0 M 30 right frontal 14,7 -
4 AH208 0 M 29 frontal 18.6 -
5 88S7594 0 M 29 cerebellum 12.2 -
6 BJ22 0 F 16 right temporal 17.6 -
7 AH33 0 F 14 left frontal 9.1 -
8 98S1246 0 F 51 left frontal 8.1 + 
9 97S2602 0 M 29 left frontal 6.9 + 
10 92S4279 AO M 57 right hemisphere 7.4 -
11 93S14308 AO M 70 left fronto-parietal 10.4 -
12 87S4007 AO F 70 corpus callosum 14.4 + 
13 98S841 AO M 39 � right frontal 13.9 + 
14 91S5273 AO F 61 bifrontal 6.6 + 
15 97S14327 AO M 39 left frontal 10 + 
16 97S12091 AO F 46 temporal lobe 13 -
17 97S1137 AO M 60 left frontal 21.6 + 
18 HZ7 AO M 41 left frontal lobe 7.8 -
19 89S361 OA M 7 cerebum 11.6 -
20 96S8667 OA F 50 corpus callosum 13.6 -
21 98S1627 OA M 42 occipital lobe 13.8 + 
22 97S9555 AOA F 51 left frontal 8.2 + 
23 97S12840 AOA F 46 left hemisphere 15.5 -
Ependymal Tumors 
24 87A148 E F 3 right frontal 13.1 -
25 87S3784 E M 25 IV ventricle 12.4 -
26 WC36 E F 14 right parietal lobe 12 -
27 90S3819 E M 60 cervical spinal cord 13.5 -
28 91S10628 E F 31 frontal lobe 10.8 + 
29 93S2357 E F 27 thoruic spinal cord 14.3 -
30 95S11784 E F 12 right parietal lobe 11.9 + 
31 95S17381 E M 40 cervical spinal cord 13.3 -
32 96S12692 E F 12 cerebellum 10.2 -
33 AH240 E M 8 cerebellar vermis 11.7 -
34 97S4312 E F 40 cervical spinal cord 10.4 -
35 AH307 E M 28 cerebellar vermis 10.6 -
36 97S15348 Sub F 43 lateral ventricle 11.4 -
37 90S4613 ^ M 27 rightthalamus l_J_ -
tel ;ict= telomerase activity; M= male; F= female; +: positive; - : negative; Sub= subependymoma 
E= ependymomas; AE= anaplastic ependymomas; 0= oligodendrogliomas; OA= oligoastrocytomas 
































































































































































































































































































































































































































































































The mean TRF length of telomerase-negative tumors was slightly longer than 
telomerase-positive tumors although the difference was not statistically significant 
(P=0.424, student's t-test). 
^ 
Besides categorizing the tumors into telomerase-positive or telomerase-
negative tumors, the correlation level between tumor grading and TRF length was 
also interesteing. Therefore, these tumors were categorized in the other way, i.e. 
grade II and grade III (anaplastic). The mean TRF length of grade III 
oligodendroglial tumors was 11.71 kb ranging from 6.6 kb to 21.6 kb while the 
mean TRF length of grade II tumors was 13.12 kb with a range from 6.9 kb to 18.6 
kb. However, there was also no statistically difference between the mean TRF 
lengths ofthese 2 groups (P= 0.424, student's t-test). 
The shortest TRF length in oligodendroglial tumors was a telomerase-positive 
anaplastic oligodendroglioma (91S5273; Fig.IV.4) and the patient's age was 61 
years old. The oligodendroglial tumors showed the longest TRF length (21.6 kb) 
was a telomerase-positive anaplastic oligodendroglioma (97S1137; Fig.IV.4) 
located on frontal lobe and the patient's age was 60 years old. 
Ependymal Tumors 
Two of 14 ependymal tumors were telomerase positive and the TRF length of 
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Fig.IV.4. TRFs in oligodendrogliomas. (A) case 91S5273 has the 
shortest TRF length 6.6kb. (B) case 97S1137 has the longest TRP 
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Fig.IV.5. TRFs in ependymal tumors. Lane 1-5: case 90S4613 
(7.7kb), 90S10628 (10.8kb), 93S2357 (14.3kb), 97S15348 (11.4kb) 
and 95S11784 (lL9kb) respectively. (See Section IIL2.5.) 
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Fig.IV.5). On the other hand, the mean TRF length of telomerase-negative 
ependymomas (n=12) was 11.72 kb with a range from 7.7 kb to 14.3 kb. Five 
samples had length greater than 12 kb, 6 samples ranged from 10-12 kb and only 1 
， . 
case was less than 10 kb. The TRF lengths of the two telomerase-positive 
ependymomas were similar to the mean TRF length of telomerase-negative 
ependymomas. The tumor showed the shortest TRF length (7.7 kb) was a 
telomerase-negative recurrent anaplastic ependymoma located on thalamus 
(90S4613; Fig.IV.5) and the patient's age was 27 years old. The one showed the 
longest TRF length (14.3kb) was a classical grade II, telomerase-negative, spinal 
cord ependymoma (93S2357; Fig.IV.5) and the patient's age was also 27 years old. 
The single ventricular subependymoma showed medium TRF length of 11.4 kb 
(97S15348; Fig.IV.5) and the patient's age was 43 years old. 
103 
IV.3. hTERT and hTEPl mRNA Expression Study  
The m R N A expression of telomerase catalytic subunit (hTERT) and 
、 associated protein (hTEPl) were investigated in 14 oligodendroglial tumors (10 
oligodendrogliomas and 4 oligoastrocytomas) and 12 ependymal tumors, p-actin 
was expected to express in all samples and used to confirm the quality of R N A and 
c D N A used in this study. Those samples which did not show p-actin expression 
was excluded and cases with negative expression of hTEPl and hTERT were 
repeated once. The m R N A expression of hTERT and hTEPl from some 
representative cases are illustrated in Fig. IV.6. A detailed expression status and 
telomere length on all samples is shown in Table IV.4. A summary of statistical 
calculation on expression frequency is shown in Table IV.5. 
Oligodendroglial Tumors 
Out of the fourteen oligodendroglial tumors, eight were telomerase-positive 
and the other six were telomerase-negative. All (8/8) of the telomerase-positive 
oligodendroglial tumors and 3 of 6 (50%) telomerase-negative oligodendroglial 
tumors expressed hTERT. The expression frequency was significantly lower in 
telomerase-negative tumor samples (P=0.024,chi-test). As for the hTEPl 
expression, 7 of 8 (87.5%) telomerase-positive tumors and 6 of 6 (100%) 
telomerase-negative tumors expressed hTEPl. The expression frequency was 
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Fig. IV.6. m R N A expression of hTERT and hTEPl. RT-PCR was used to 
examine the expression of hTERT and hTEPl gene in oligodendroglial and 
ependymal tumors. M: size marker. Lane 1: a positive control which expressed 
hTERT and hTEPl. Lane 2-4: telomerase-positive (tel +) oligodendrogliomas 
(97S2602; 95S16128; 91S5273). Lane 5: telomerase-negative (tel -) 
oligodendrogliomas (BJ22). Lane 6-8: telomerase-negative ependymomas 
(97S4312; AH307; WC36). Lane 9-10: telomerase-positive ependymomas 
(95S11784; 91S10628). P-actin was used as an internal control. 
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Table IV.4. Summarized results ofTRF length, hTERT, hTEPl mRNA expression 
on oligodendroglial and ependymal tumors 
case surgical no sexy'age site tumor tel act TRF hTERT hTEPl  
subtype iength(kb)  
Oligodendroglial Tumors 
I 88S216 M/67 left occipital 0 - 15.5 ND ND 
� 2 88S3489 F/78 right temporal 0 - 15.7 ND ND 
‘ 3 88S5759 M/30 right frontal 0 - 14.7 ND ND 
4 97S2602 M/29 left frontal 0 + 6.9 + + 
5 AH33 F/14 left frontal 0 - 9.1 ND ND 
6 88S7594 M/29 cerebellum 0 - 12.2 ND ND 
7 95S16128 M/35 parietal lobe 0 + ND + -
8 AH208 M/29 frontal lobe 0 - 18.6 ND ND 
9 BJ22 F/16 right temporal 0 - 17.6 - + 
10 98S1246 F/51 left frontal 0 + 8.1 ND ND 
II 92S4279 M/57 right hemisphere AO - 7.4 + + 
12 93S14308 M/70 left fronto-parietal AO - 10.4 ND ND 
13 87S4007 F/70 corpus callosum AO + 14.4 + + 
14 98S841 M/39 right frontal AO + 13.9 + + 
15 91S5273 F/61 bifrontal AO + 6.6 + + 
16 HZ7 M/41 left frontal lobe AO - 7.8 ND ND 
17 97S12091 F/46 temporal lobe AO - 13 - + 
18 97S14327 M/39 left frontal AO + 10 ND ND 
19 95S11370 M/59 frontal lobe AO + ND + + 
20 97S1137 M/60 left frontal AO + 21.6 + + 
21 96S8667 F/50 corpus callosum OA - 13.6 - + 
22 98S1627 M/42 occipital lobe OA + 13.8 + + 
23 89S361 M/7 cerebum OA - 11.6 ND ND 
24 95S9300 F/43 right frontal lobe OA - N D + + 
25 97S9555 F/51 left frontal AOA + 8.2 ND ND 
26 97S12840 F/46 left hemisphere AOA - 15.5 + + 
Ependymal Tumors 
27 87A148 F/3 right frontal E - 13.1 - -
28 87S3784 M/25 IV ventricle E - 12.4 ND ND 
29 WC36 F/14 right parietal lobe E - 12 - + 
30 90S3819 M/60 cervical spinal cord E - 13.5 - + 
31 91S10628 F/31 frontal lobe E + 10.8 + + 
32 93S2357 F/27 thoruic spinal cord E - 14.3 ND ND 
33 95S11784 F/12 right parietal lobe E + 11.9 + + 
34 95S17381 M/40 cervical spinal cord E - 13.3 - + 
35 96S12692 F/12 cerebellum E - 10.2 - + 
36 AH240 M/8 cerebella vermis E - 11.7 - -
37 97S4312 F/40 cervical spinal cord E - 10.4 - + 
38 AH307 M/28 cerebella vermis E - 10.6 - + 
39 96S11222 F/39 cauda equina Myx - ND - -
40 97S15348 F/43 lateral ventricle Sub - 11.4 ND ND 
41 90S4613 U121 right thalamus ^ - 7.7 - + 
tel act= telomerase activity; F= female; M=male; + positive; - negative; ND= not done 
Myx=myxopapillary ependymoma; Sub= subependymoma; E= ependymomas; AE= anaplastic ependymomas 


































































































































































































































































































For the three hTERT positively expressed telomerase-negative 
oligodendroglial tumors, they were anaplastic oligodendrogliomas (92S4279), 
grade II oligoastrocytoma (95S9300) and anaplastic oligoastrocytomas (97sl2840). 
， . 
The single hTEPl negatively expressed, telomerase-positive oligodendroglial tumor 
was a grade II recurrent oligodendroglioma (95S16128; Fig.IV.6). 
Ependymal Tumors 
Two of twelve ependymal tumors were telomerase positive and both of them 
expressed hTERT. On the other hand, all the twelve telomerase-negative 
ependymal tumors did not show hTERT expression. As for the hTEPl expression, 
2/2 (100%) of telomerase-positive ependymal tumors showed expression but only 
7/10 (70%) of telomerase-negative ependymal tumors expressed hTEPl. 
For the three hTEPl negatively expressed ependymomas, one of them was the 
myxopapillary ependymoma (96S11222). The other two were conventional 
ependymomas and both of the patients had age under 10 years old (87A148, 
AH240). Both of the recurrent tumors showed hTEPl but not hTERT expression 
and one of them was anaplastic. 
108 
IV.4. pl6 and pRb Protein Expression  
Protein expression of pl6 and pRb was investigated in 22 oligodendroglial 
� . 
tumors (16 oligodendrogliomas and 6 oligoastrocytomas) and 15 ependymal tumors 
by immunohistochemistry for a relationship between expression and telomerase 
activity. A detailed expression status on all samples is shown in Table IV.6. A 
summary of statistical calculation on expression frequency is shown in Table IV.7. 
Loss of pl6 Expression 
Of the 22 oligodendroglial tumors, 15 samples (68 % ) showed negative pl6 
nuclear expression. If they were divided into telomerase-positive and negative 
groups, 8 of 11 (73 % ) telomerase-positive tumors and 7 of 11 (64%) telomerase-
negative tumors showed negative pl6 nuclear expression. The pl6 alteration rate 
was not statistically different between telomerase-positive and telomerase-negative 
oligodendroglial tumors ¢)=0.647, chi-test). Nuclear expression of pl6 was 
negative in 12 of 14 (86%) ependymal tumors. Eleven of 12 telomerase-negative 
and 1 of2 telomerase-positive ependymal tumors showed aberrant pl6 expression. 
Fig.IV.7 illustrates the positive pl6 staining in our tumor sample. 
109 
Table rV.6. The clinical data andpl6, pRb protein expression on oligodendroglial 
and ependymal tumors 
case no. surgical no. sex/age tumor site tumor tel act immunohistochemistry  
subtype £^6 pRb 
Oligodendroglial tumors 
I 87S7123 M/33 frontal lobe 0 - - + 
� 2 88S216 M!61 left occipital 0 - + + 
3 88S3489 F/78 right temporal 0 - + + 
4 88S5759 M/30 right frontal 0 - - + 
5 88S7594 Mi29 cerebellum 0 - - NE 
6 95S16128 M/35 parietal lobe 0 + - NE 
7 97S2602 M/29 left frontal 0 + - + 
8 98S1246 F/51 left frontal 0 + + + 
9 87S4007 F/70 corpus callosum AO + - NE 
10 98S841 M/39 rightfrontal AO + - + 
II 91S5273 F/61 bifrontal AO + + + 
12 95S11370 M/59 frontal lobe AO + - + 
13 97S1137 M/60 left frontal AO + - + 
14 92S4279 M/57 right hemisphere AO - + + 
15 93S14308 M/70 left fronto-parietal AO - - + 
16 97S14327 M/39 left frontal AO + - + 
17 98S1627 M/42 occipital lobe OA + + + 
18 89S361 W 1 cerebum OA - - NE 
19 95S9300 F/43 right frontal OA - - + 
20 96S8667 F/50 corpus callosum OA - + + 
21 97S9555 F/51 left frontal AOA + - + 
22 97S12840 F/46 left hemisphere AOA - - + 
Ependymal tumors 
23 87A148 F/3 right frontal E - + NE 
24 87S3784 M/25 IV ventricle E - - + 
25 90S3819 M/60 cervical spinal cord E - - NE 
26 91S10628 F/31 frontal lobe E + - + 
27 93A179 M/10 cervical spinal cord E - - + 
28 93S2357 F/27 thoruic spinal cord E - ND NE 
29 95S11784 F/12 right parietal lobe E + + + 
30 95S17381 M/40 cervical spinal cord E - - + 
31 96S5660 F/35 cervical spinal cord E - - + 
32 96S12692 F/12 cerebellum E - - + 
33 97S4312 F/40 cervical spinal cord E - - + 
34 87S7371 M/27 cauda equina Myx - - + 
35 96S11222 F/39 Cauda equina Myx - - + 
36 97S15348 F/43 lateral ventricle Sub - - + 
37 90S4613 M/27 rightthalamus ^ ： ： + 
tel act= telomerase activity; F= female; M=male; + positive; - negative; ND= not done; NE=nonevaluable 
0 = oligodendroglioma; A0= anaplastic oligodendroglioma; OA= oligoastrocytoma; AOA= anaplastic 
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Fig. IV.7. Immunohistochemical stain for pl6 tumor suppressor protein in 
an anaplastic oligodendroglioma (91S5273). Magnification, X20. 
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pRb Protein Expression 
pRb protein was detected in 18 of 22 (81.8%) oligodendroglial tumors while 
， the other four samples (18.2%) were not evaluable. For the ependymal tumors, 12 
of 15 (80%) tumor samples were pRb positive including the two telomerase-
positive cases and three cases (20%) were not evaluable. Besides those 
nonevaluable cases, pRb was expressed in all evaluable oligodendroglial and 
ependymal tumor samples. No correlation between pRb expression and telomerase 
activity status was observed. On the other hand, there was an inverse relationship 
between pl6 and pRb observed in 11 ofl8 evaluable oligodendroglial tumor and 11 
of 12 evaluable ependymal tumor cases. Fig. IV. 8 illustrates a pRb postive case. 
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Fig. IV. 8. Immunohistochemical stain for pRb protein in a 
telomerase-positive anaplastic oligodendroglioma (98S841). It 
reveals that pRb is expressed in the nucleus of tumor cells 
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V.1. Telomerase Activity in Gliomas  
General Discussion 
In this study, telomerase activities from a broad spectrum of astrocytic and 
non-astrocytic gliomas were examined since only small numbers of non-astrocytic 
gliomas were studied at the time when we decided to start this project. Our results 
showed that telomerase activities were detected in grade II and higher grade tumors 
but absent in grade I tumors. 
Telomerase activation is believed to be involved in tumorigenesis and 
immortalization of cells (Kim et al., 1994; Rhyu, 1995). All low-grade gliomas in 
this study were devoid of telomerase activity including pilocytic astrocytomas, 
D N T and PXA. D N T is regarded as quasiharmatomatous but a small proportion of 
PXA, generally a benign tumor, are documented to transform to high grade tumors 
(Rosenblum et al., 1996). Though the number of cases is small, that low-grade 
tumors exhibit no telomerase activity may explain the current difficulties in 
establishing immortalized cell lines from these tumors ^ >ersonal communication, 
Dr.D.D.Bigner). 
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In section 1.5.1, the telomerase activity expression frequencies in brain 
tumors were discussed and the studies on telomerase activities in some common 
brain tumors including our results were summarized in Table L4. The expression 
’ 
frequency of oligodendroglial and ependymal tumors in our study showed a minor 
changes when additional cases were added. Table V.1 shows an overview on our 
finalized result and the comparison to other groups studying the same kind of 
tumors. High percentage of oligodendrogliomas was detected as telomerase 
positive in most ofthe studies. Langford et al (1995) performed the largest scale 
study on oligodendrogliomas (n=19) besides ours and they showed 100% 
expression frequency in oligodendrogliomas. However, most of the studies 
including Langford's study (Langford et al., 1995) did not state the grade of the 
oligodendrogliomas they examined. Therefore the high percentage expression 
frequency observed in grade two samples or anaplastic samples or in both of them 
was unknown in these studies. In our study, we have higher expression 
frequency in anaplastic (58.3%) than in grade II oligodendrogliomas (27.3%) 
although the difference was not statistically significant (P= 0.134, chi-test). It 
suggests the role of telomerase activation in tumorigenesis. The same feature also 
applies to oligoastrocytomas (grade II: 25%; grade III: 50%; P= 0.545, chi-test). 
DeMasters et al (1997) also detected activity in 1 anaplastic oligodendroglioma but 
not in the grade II oligodendroglioma. In contrast, Weil et al (1999) showed that 
both of the grade II and anaplastic oligodendrogliomas were telomerase positive 
with the use of selective tissue microdissection. It might due to the increased 







































































































































































































































































































































































































































































































































































































pure tumor cells. The proportion of telomerase-positive oligodendrogliomas 
detected in the studies ofLangford et al (1995), Hiraga et al (1998) and Nakatani 
et al (1997) and our study were even higher than those for glioblastomas and 
� 
anaplastic astrocytomas and this showed that telomerase activation level might be 
different in different neoplastic cell types. Most of the tumors that have been 
shown to be telomerase-positive so far were malignant tumors. In this study, 
conventional ependymomas had an expression frequency of 13.3% but none in the 
myxopapillary variant, subependymoma and anaplastic ependymoma though 
admittedly the number of cases examined was small. However, no enzyme 
activity were detected in the studies of DeMaster et al (1997), Hiraga et al (1998) 
and Sano et al (1998). The low detection rate in ependymal tumors is consistent 
with its protracted indolent clinical course (Kleihues et al., 1993). 
Generally, glioblastomas usually have the highest expression frequency in the 
astrocytoma category. Most of the groups including ours have higher telomerase 
positivity in G B M than anaplastic and grade II astrocytomas. Only Sallinen et al 
(1997) and Morii et al (1997) did not show this trend in their studies due to very 
small sample size. For all the other groups, Langford et al (1995), Le et al 
(1998), Hiraga et al (1998), Nakatani et al (1997) and Sano et al (1998)，they all 
detected much lower telomerase expression frequency in anaplastic astrocytomas 
than G B M . However, the prognosis of anaplastic astrocytomas differs only 
marginally from that of G B M (Kleihues et al., 1993) and anaplastic astrocytomas 
have acquired most of the genetic aberrations pertaining to G B M (von Deimling et 
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al., 1995). Moreover, inadequate tissue sampling in neurosurgical procedure does 
not always distinguish the two categories with certainty (Langford et al., 1995; 
DeMasters et aL, 1997). Besides Le et al (1998) and Weil et al (1999), the 
�-
telomerase expression frequency of G B M in both our and other studies are still 
significantly less than those observed in other malignant tumors, e.g. 94% for 
neuroblastoma (Hiyama E et al.，1995)，87.5% for head and neck squamous cell 
carcinoma (Mutirangura et al.，1996). Since the prognosis for grade III and IV 
astrocytomas lies only between 1 and 2 years, these findings are consistent with the 
hypothesis that astrocytomas may have alternate mechanisms triggering cellular 
proliferation other than those involving telomerase activation (Langford et al., 
1995; DeMasters et al., 1997). This hypothesis was also strengthened by the 
observation that the telomere length of astrocytomas was not uniformly increased 
(Numberg et al., 1993). 
Interestingly, the mean age of telomerase-positive malignant astrocytomas 
patients (61.7 years) was significantly higher than that for telomerase-negative 
patients (47.8 years, P=0.002). This is in keeping with the recent observation that 
at least in malignant astrocytomas, there may be two subtypes differing by age: 
type I tumors affect younger patients and have better prognosis than type II patients 
who are generally older. The two groups also have significant differences in their 
molecular genetics with respect to p53 mutations and epidermal growth factor 
receptor amplification (Watanabe et al.，1996). The lower telomerase expression 
frequency in younger patients found in this study suggesting lower cellular 
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proliferation is consistent with this molecular classification. Interestingly, in this 
study, the telomerase expression frequencies were similar in grade II (23.1%), 
grade III (23.1%) and grade IV (26.3%) astrocytomas, suggesting that telomerase 
> 
activation was probably an early event in the molecular genesis of astrocytomas, 
similar to some observations of the p53 gene, which also had a relatively constant 
mutation rates across the different grades of astrocytomas (Walker & Lavin, 1997; 
Patt et al., 1996; Lang et al., 1994). 
Limitation and Sensitivity 
The discrepancy of results among our and other groups' telomerase activity 
studies may be due to different laboratory conditions. For instance, we used a 
commercially available telomerase detection kit while other research groups did 
not. The reverse primer (RP) we used had a modified primer sequence which was 
different from the original C X primer in order to reduce amplification artifacts. It 
was recently reported that false positive results might occur in original reaction 
conditions due to the subsequent staggered annealing of C X and TS primer dimer 
(Kmpp et al., 1997). Besides, we could not exclude that some telomerase 
inhibitors might be present in our cases even though the internal standard could be 
amplified and the sensitivity was limited by 100 control cells after 27 PCR cycles. 
Therefore, the theoretical possibility exists for a false negative in tumors with very 
sparse telomerase-expressing cells. Also, the number of cases examined in some 
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of these series were small and possibilities for differences in classification and 
grading exist, which may also account for the discrepancies. 
•» 
Tissue quality is another limiting factor in telomerase activity detection 
analysis. Besides protein degradation, R N A degradation is also crucial for 
experiment accuracy because telomerase use its R N A template for telomere 
elongation and telomerase activity necessitates an active protein and a non-
degraded RNA. Therefore the time between surgery and freezing tumor tissues is 
relatively important. A study showed that no detectable telomerase activity was 
observed in most cases with complete R N A degradation (Yan et al., 1998), 
illustrating the importance of tissue quality. 
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V«2. Telomere Length in Oligodendroglial and Ependymal Tumors 
Besides telomerase activity status, telomere length of tumors was frequently 
， altered. To further investigate the role of telomere and telomerase in the 
pathogenesis of non-astrocytic tumors, telomere length of oligodendroglial and 
ependymal tumors was measured and the correlation between telomerase activity 
and telomere length was examined. 
General Discussion 
A number of studies reported that telomere length alteration was observed in 
cancerous tissue and most of them showed telomere reduction ps[umberg et al., 
1993; Hastie et al., 1990; Morii et al., 1997; Hiraga et al., 1998; Ohashi et al., 
1996). Our result is listed in Table IV.2. In our study, telomerase activity and 
telomere length were compared and a slightly shorter mean TRF length in 
telomerase-positive oligodendroglial tumors was observed although they were not 
statistically significant (11.50 kb vs. 13.05 kb, P=0.424). Most of the telomerase-
negative oligodendroglial tumors (11/14) had TRF length greater than 10 kb while 
44% (4/9) of telomerase-positive tumors had length less than 10 kb. One of the 
two telomerase-positive ependymal tumors had shorter telomere length (10.8 kb) 
than the mean TRF length of telomerase-negative ependymal tumors (11.72 kb) but 
the other one did not (11.9 kb). A similar finding was reported in Morii et aI,s 
study (Morii et al.，1997). They compared the telomere length in telomerase-
positive and telomerase-negative tumors with astrocytic differentiation: the 
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telomerase-positive tumors had a mean TRF length less than 10 kb while 
telomerase-negative tumors all had long heterogeneous TRFs which exhibited an 
increase signal peak from 10 to 20 kb. A similar feature was observed in our non-
�. 
astroctyic tumors in which our telomerase-positive oligodendroglial tumors had a 
mean TRF length around 10 kb and most of our telomerase-negative tumors also 
exhibited signal peak from 10 to 20 kb. 
Alternative Lengthening of Telomeres 
It has been shown that in vitro immortalized telomerase-negative cell lines 
acquire very long and heterogeneous telomeres via other telomere lengthening 
mechanisms in the absence of telomerase activation, a mechanism known as 
alternative lengthening of telomeres (ALT) (Bryan et aL, 1995; Mumane et al., 
1994; Rogan et al, 1995). The detail of A L T was discussed in Section I.4.9. In 
our study, most of the telomerase-negative tumor samples did not exhibit long 
telomeres. However, two telomerase-negative tumors (AH208, BJ22; Table 
IV.2.) showed relatively long telomeres but they are still shorter than those 
reported cases with A L T which characteristically had telomere lengths greater than 
20kb (Bryan et aL, 1995; Mumane et al., 1994; Rogan et al., 1995). There were 
also a few telomerase-negative cases in our study that showed relatively short 
telomere lengths (AH33, HZ7, 92S4279; Table IV.2.). It is possible that there 
may be other non-telomerase mechanisms of telomere maintenance that do not 
result in very long telomeres. 
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Possible Mechanisms ofALT 
There are two possible mechanisms used by eukaryotes for maintenance of 
telomere length: recombination and retrotransposition. It has been proposed that 
•» 
the normal-length telomeres are capped with proteins that prevent recombination 
events in the presence of telomerase activity, but severely shortened telomeres will 
become uncapped, thus promoting recombinational repair (McEachem & 
Blackbum, 1996). A similar mechanism was previously proposed to explain the 
rapid elongation of short telomeres in a telomerase-negative human cell line 
(Mumane et al., 1994). Other study suggests that telomerase can mediate the de 
novo addition of telomere sequence in the healing of broken chromosomes further 
support the possibility that A L T may involve recombination (Flint et al., 1994). 
On the other hand, retroposons are utilized instead of short repeat sequences 
to replace the sequences lost from the end of chromosomes during cell division in 
fmit fly Drosphilia melanogaster (Reddel et al., 1997). In view of the above 
considerations, both recombination and retrotransposition should be considered as 
candidate mechanisms of ALT. However, there might be some other unknown 
A L T mechanisms involved in telomere elongation. If the above mechanisms 
might be one of the A L T mechanisms, it seems likely that normal somatic cells 
contain repressors of ALT. A large number of genes encoding helicases, 
topoisomerases and polymerases have been identified that repress homologous 
recombination in yeast (Klein, 1995), so it is possible that the human homologs of 
one or more of these gense may be responsible for repressing A L T in normal 
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mammalian cells. Although there are evidences that A L T occurred in some tumor 
samples, we cannot exclude the possibility that there may be telomere-maintenance 
mechanisms other than telomerase that do not result in abnormally lengthened 
， 
telomeres e.g. some of our telomerase-negative cases showed short telomere length. 
Other Models 
Besides the possibility of ALT, an alternative model is that these cell lines 
possess telomerase that is active in vivo, but mutant in at least one of its subunit. 
Presumably, the mutation has two effects: (1) a dysregulation of telomerase activiy 
in vivo, resulting in abnormal lengthening of telomeres; and (2) the inability of 
telomerase to use an oligonucleotide as an in vitro substrate. This possibility is 
still under investigation. The very long TRFs observed may also be due to the 
modification of subtelomeric D N A instead of truly reflect long stretches of 
telomeric repeats (Bryan et al., 1995). TRF itself cannot distinguish the elongation 
of telomeric repeats from a modification of the subtelomeric sequence, for instant, 
methylation. This prevents digestion at the subtelomeic restriction site and result in 
overestimation of telomere length (Bryan et al., 1995). 
Chromosome 2 
Recently, an unidentified gene on chromosome 2 regulating the telomere 
length in mouse is demonstrated (Zhu L et aL, 1998) and this makes the 
mechanisms of telomere length alterations become more complicated. The genetic 
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regulation of telomere length was investigated by using two inter-fertile species of 
mice, whereas one has long telomeres phenotypes and the other has short telomere. 
They were used to generate F1 crosses and reciprocal backcrosses, which were then 
� 
analyzed for regulation of telomere length. An 5-centimorgan region on distal 
chromosome 2 that predominantly controls the observed species-specific telomere 
length regulation was identified. Further investigation on this gene may help to 
understand the molecular mechanism of telomere regulation. 
Limitation and Sensitivity 
The accuracy of telomere length study is probably due to the limitation of 
actual telomere length measurement. So far, there is no method to measure the 
actual telomere length in cells. TRFs represent a peak telomere length in tissues 
and cells population. This only shows mean telomere length in cells and limits its 
use to correlate between telomerase activity and telomere length. 
Experimentally, the accuracy of data is probably limited by the reading error 
since the distance of band traveled was read from a ruler. Besides, there is always 
some shift of actual signal peak position after hybridization because the size of 
membrane cannot be exactly the same as the size of the gel. Moreover, the TRFs 
was read from a standard curve, therefore the linearity of standard curve strongly 
affect the result. The small sample size also affects the accuracy of correlating 
telomerase activity with telomere length. In our study, the statistical correlation 
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between telomerase activity and telomere length cannot be conclusive in 
ependymal tumors since only two of them were telomerase positive. 
n 
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V.3. hTERT and hTEPl mRNA Expression in Oligodendroglial 
and Ependymal Tumors  
General Discussion 
*» 
Three major components of human telomerase, human telomerase R N A 
(hTR), telomerase-associated protein (hTEPl) and the catalytic subunit of 
telomerase (hTERT) were recently cloned (Feng et al., 1995; Harrington et al., 
1997; Nakamura et al., 1997). However, the roles of these subunits play in the 
regulation of telomerase activity remain unclear. In this study, we focused on the 
hTERT and hTEPl m R N A expression since hTR R N A expression was examined in 
brain tumors by some research groups before and it was found to be widely 
expressed in both cancerous and noncancerous tissues (Morii et al., 1997; Sallinen 
et al., 1997; Rushing et al., 1997). hTERT m R N A expression was analyzed in 
some tumors and it was found that hTERT m R N A expression was correlated very 
well to the telomerase activity fNakayama et al., 1998; Takakura et al., 1998). 
Our result on hTERT m R N A expression is consistent with the results from other 
groups. Although hTERT m R N A was expressed in some telomerase-negative 
oligodendroglial tumors, the expression frequency was significantly higher in 
telomerase-positive tumors (P=0.024, chi-test) and the hTERT m R N A expression 
was found exclusively in telomerase-positive samples of ependymal tumors. A 
recent study demonstrated that 90% of the gastric carcinomas had an increased 
hTERT expression compared with that of the corresponding non-neoplastic 
mucosas (Yasui et al., 1998). Results from our studies and those of others suggest 
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that hTERT expression is a rate-limiting determinant of the enzymatic activity of 
human telomerase and expression of hTERT transcript is required for telomerase 
activation (Takakura et al., 1998; Kanaya et al., 1998). 
>. 
On the other hand, hTERT m R N A expression in some telomerase-negative 
tumors also suggested that expression does not always lead to telomerase 
activation. Besides our study, there are also some studies that showed discordant 
cases, in which telomerase activity was observed but hTERT m R N A expression 
was negative or vice versa (Kanaya et al., 1998; Takakura et al., 1998). These 
suggest the possibility that other factors may substitute for the hTERT subunit in 
conferring full enzymatic activity or the levels of expression of each subunit and 
the balance of the levels of expression of these subunits might play a critical role in 
determining telomerase activity. It is also possible that post-transcriptional 
modification ofhTERT alters the enzymatic activity of telomerase. 
There are evidences showed that the transcriptional control of the hTERT 
gene and alternate splicing of hTERT transcripts are the two main regulatory 
mechanisms controlling the activity of telomerase (Ulaner et al., 1998). The 
hTERT transcript undergoes alternative splicing in several tissues and cell lines 
(Kilian et al., 1997; Ulaner et al., 1998). The function of these alternate 
transcripts is still unknown, although the position of the splice sites suggests that 
many of the alternate transcript do not code for functional reverse transcriptases. 
Only the full length hTERT transcript would be expected to code for an active 
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reverse transcriptase. These further suggest the critical role of hTERT in 
controlling telomerase activity. It is possible that the translated proteins from 
spliced transcripts could serve as regulators of telomerase activity. This alternate 
� 
splicing mechanism suggest that it is likely that the cell must overcome both the 
transcriptional repression of the hTERT gene and alternate transcript before 
telomerase activation and it may explain why some tumors in our study were 
hTERT positively expressed but did not show detectable telomerase activity. 
In contrast to hTERT expression, the expression of hTEPl, which is 
presumably the other subunit of telomerase, is widely expressed in our tumor 
samples. There is no correlation observed between the hTEPl expression and 
telomerase activity in our tumor samples and it is consistent to the previous reports 
on other tumors P^akayama et al., 1998; Takakura et al.,1998). Although hTEPl 
was found to interact with telomerase, our findings failed to determine the role of 
hTEPl in telomerase regulation. It suggests that this subunit is unlikely to be rate 
limiting for enzyme activity. Nakayama et al (1997) have suggested that hTEPl 
may function as a regulatory subunit for telomerase activity following its post-
transcriptional modification. However, further biochemical analyses are needed 
to clearly determine the role ofTPEl in telomerase regulation. 
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Limitation and Sensitivity 
RT-PCR is a molecular technique which requires small quantity of R N A . It 
� . 
is a sensitive method in which less than l^ ig of R N A can be used for reverse 
transcription and some commercial kit require as low as lOpg total R N A for their 
RT-PCR reaction. However, it is still possible that no P C R product could be 
observed if there is insufficient amount of R N A present in tissues. Besides, the 
integrity of R N A is also important because R N A is easily degraded. Therefore an 
internal control primer was included in our study to examine the quality of R N A . 
All the tumor samples included in this study was in good quality. D N A 
contamination is also a problem to R N A work but m R N A specific primers are 
chosen (Section III.3.3.1) to exclude this possibility in our study. However, our 
study is only qualitative and can be improved by measuring the expression levels of 
those subunits from the tumor tissues and adjacent tissues by in situ hybridization. 
Telomerase inhibitors is another factor that may affect the result. Some 
hTERT positively expressed cases showed telomerase negative might due to the 
inhibition from telomerase inhibitors which cannot be avoided. Changes in 
telomerase activity status affects the statistical correlation between expression and 
telomerase activity. Beside the telomerase inhibitors, small sample size in this 
study also limits the investigation on the relationship between expression and 
telomerase activity. 
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V.4. Protein Expression ofpl6 and pRb in Oligodendroglial and 
Ependymal Tumors  
� General Discussion 
Recently, it has been proposed that both the inactivation of the Rb/pl6^4a 
pathway and telomerase activation are required to immortalize human epithelial 
cells (Kiyono et al., 1998). pl6^^^^^ gene locates at 9p21 which encodes a protein 
that binds to cyclin-dependent kinase 4 (CDK4). This prevents the formation of 
the CDK4/cyclin D complexes which is required for the phosphorylation of the 
pRb protein, a prerequisite for progression of normal cells from G1 into S phase of 
the cell cycle. In this part of study, pl6 and pRb expression was examined by 
immunohistochemistry for a relationship between expression and telomerase 
activity. 
No correlation was observed between pl6 or pRb with telomerase activity in 
both oligodendroglial and ependymal tumors. Loss of pl6 expression was widely 
observed in both telomerase-positive and telomerase-negative tumor samples, pl6 
gene mutation or deletion was rarely found in oligodendroglial and ependymal 
tumors but protein expression was not examined in these tumors previously (Sato et 
al., 1996; Jen et al., 1994). The rate of altered expression of pl6 is relatively high 
in this study and is similar to what has been found in glioblastoma multiforme in 
which 80 % of tumor samples showed pl6 immnunohistochemical negativity 
(Burns et al., 1998). Previous studies showed that immortalization was associated 
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with loss of pl6 expression (Vogt et al., 1998; Noble et al., 1996). Besides, 
Landberg et al (1997) demonstrated that down regulation of pl6 was not related per 
se to telomerase activity, but high telomerase activity could be observed when 
>. 
together with cyclin D overexpression. This is consistent with our result in which 
no correlation was observed between telomerase activity and pl6 expression alone. 
In contrast to pl6, no alteration of pRb expression was observed in all the 
evaluable cases. Recently, a study demonstrated that overexpression of full length 
Rb resulted in significant downregulation of telomerase activity ^ s[guyen et al., 
1999). However, the expresssion level of pRb and telomerase activiy was not 
quantified in our study. Although both pl6/pRb inactivation and telomerase 
activity were observed to be required for immortalization in some immortalized cell 
lines (Kiyono et al., 1998; Rogan et al., 1995), no correlation was found in the 
non-astrocytic gliomas in this study. 
Limitation and Sensitivity 
This study is probably limited by the absolute amount of antigen in a sample. 
There is a possibility that antigen in the sample is already degraded, especially pl6 
is a comparatively unstable protein (Geradts et al., 1995). Antigen could be 
degraded over certain time or during retrieval step. Some people suggested that 
microwave retrieval method might cause false negative result (Polak & Noorden, 
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1997). Besides, over-fixation or under-fixation of tissue would also affect the 
amount of antigen present and poor penetration of fixative or over-fixed of the 
peripheral area may reduce the immunoreactivity. Besides the amount of antigen, 
� 
manual cell counting might also introduce some experimental inconsistency. 
Different field area or subjective observation might end up with different result. 
Sample size should be increased or further combine with other technique is needed 
to confirm the result. 
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V.5. Discussion on Telomerase Activity-Related Factors  
Besides the several telomerase components, there are some other factors which 
‘ are investigated by other research groups and may also be telomerase activity-
related. 
Protein Kinase Ca 
It is recently reported that hTEPl and hTERT are phosphoproteins and their 
phosphorylation is a prerequisite for the activation of telomerase in an intact human 
breast cancer cell line (Li et al., 1998). Protein kinase Ca was identified to 
mediate the phosphorylation ofhTEPl and hTERT and induced a marked increase 
in telomerase activity and this activity was completely inhibited by protein 
phosphatase 2A (PP2A). These suggested that phosphorylation of hTERT and 
hTEPl by protein kinase Ca represents an essential step in generation of a 
functional telomerase complex in the initiation and maintenance of telomerase 
activity in human cancers. Of course more studies should be continued, and this 
suggested that not only the m R N A level of telomerase subunits is important, 
protein levels also play an important role in telomerase regulation. Thus, protein 
kinase Ca may be involved in tumorigenesis. 
135 
Myc Activates Telomerase 
As more research was done to investigate telomerase regulation, it seems that 
the mechanisms become more complicated than expected. A study showed that 
•% 
Myc induces telomerase in both normal human mammary epithelial cells and 
normal human diploid fibroblasts (Wang et al., 1998). Myc increases expression 
of hTERT and extends the life span of these epithelial cells. These showed that 
Myc has the ability to promote tumor formation by activating telomerase. hTERT 
promoter was shown to contain binding sites for hormone response elements and 
several transcription factors including 2 binding sites for the myc oncogene (Cong 
et al., 1999). The abundance of binding sites for potential regulatory proteins 
within hTERT promoter further suggests that hTERT expression may be subject to 
multiple levels of control and regulation by different factors in different cellular 
contexts. 
Tankyrase 
TRF 1 (see Section 1.4.5.4) is proposed as a negative regulator of telomere 
length maintenance, however, the regulation mechanism is still unknown. 
Recently, tankyrase, a poly(ADP-ribose) polymerase was identified and localized 
to human telomeres (Smith et al., 1998). Tankyrase has been shown to bind to 
the telomeric protein TRF1 and this suggested that tankyrase controls telomerase 
by removing TRF1 which blocks the access of telomerase to the chromosome ends. 
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V.6. Significance of Study and Clinical Application  
Diagnostic Marker 
,. 
Since telomerase activation is demonstrated in some of our tumor samples, 
especially in oligodendroglial tumors, telomerase appears as a potential biomarker 
for the early detection of cancer. Besides the detection in tumor samples, other 
researchers also examine the possibility of telomerase as a diagnostic tool using 
pathological specimens. Besides frozen tissues, almost any type of clinical 
specimen can be utilized to detect telomerase activity including fine-needle 
aspirates, urine, cerebrospinal fluid, washes and rinses etc. In a study of breast 
cancer, fine-needle aspirates samples yielded a sensitivity of 67%, a specificity of 
90% and a positive predictive value of 77% (Sugino et al., 1996). It helps in 
clinical diagnosis prior to surgery and in some instances when cytology is not 
informative for distinguishing carcinoma from benign disease. Besides, 
telomerase activity was found in 73% of bladder washings in patients with 
histologically confirmed bladder carcinomas and no false positive result was 
demonstrated (Muller et al., 1996). Application of telomerase assay for detecting 
low grade bladder tumor in voided urine samples yield better result than urinary 
cytology and is a less invasive method (Kavaler et al., 1998). 
Besides telomerase activity detection, telomerase subunits are also 
investigated for a possible diagnostic tool for detection of cancer. In a study of 
bladder cancer, increased levels of hTR were detected by RT-PCR in 25 of 30 
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bladder cancer patients and in 4 of 15 patients with benign urological disorders 
(Muller et al., 1998). This represents a new method of detecting malignant cells 
in urine. Another RT-PCR analysis revealed that about 80% of urinary sediments 
*» 
from patients with bladder cancer expressed hTERT m R N A while only 4 % of 
sediments from patients without urothelial lesions did (Ito et aL, 1998). In our 
study, hTERT expression was found in 11 of 14 (78.6%) oligodendroglial tumors 
also suggested that hTERT m R N A expression might be a possible diagnostic tool 
for oligodendroglial tumors. 
All of these evidences showed that detection of telomerase activity or 
telomerase components expression in clinical specimens would provide a new 
method for early detection of cancer or distinguish preneoplastic from carcinoma 
tissues which could replace the older anatomically or cytologically orientated 
methods. In cancers in which few markers have been identified, such as 
meningiomas, there is a hope that telomerase activity might provide clinicians with 
an objective staging of disease progression (Langford et al., 1997). However, 
more studies should be conducted before such a test is used in patient care. The 
acceptable specificity, sensitivity and accuracy of the assay should be found out 
and a way to preserve the clinical specimens is needed because both the R N A and 
protein is easily degraded. Moreover, the combination with other molecular 
genetic markers e.g. p53 would merit further investigation. 
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Prognostic Factor 
Besides of being a diagnostic tool, telomerase can be a prognostic tool. In 
our study, the higher the tumor grade, the higher the telomerase detection rate. 
， . 
Several studies have also shown significant association between telomerase activity 
and poor outcome. Increased expression of telomerase R N A has been correlated 
with increased cell proliferation in human astrocyotmas (Sallinen et al., 1997). In 
neuroblastomas, high telomerase activity is associated with other genetic changes 
and an unfavourable prognosis (Hiyama E et al., 1995). There is evidence also 
indicates that the level of telomerase activity in acute leukemias may mirror tumor 
progression and be of prognostic relevance QSforback & Ross, 1997). 
Therapeutic Targets 
Taken the theory that telomerase activity is likely to be required for the 
sustained proliferation of advanced tumors, telomerase inhibitors may thus provide 
an effective cancer therapy that avoids side effects in normal somatic cells that lack 
telomerase expression. Using an antisense oligonucleotide targeted to the 
template region is one approach (Glukhov et al., 1998;). Another inhibition 
strategy is the generation of mutant telomerase RNAs (Greider, 1996; Prescott & 
Blackbum, 1997; Marusic et al., 1997). Reverse transcriptase inhibitors can be 
model compounds for telomerase inhibition by interference with the polymerase 
active site of the enzyme. Azidothymidine (AZT), dideoxyguanosine (ddG), and 
3 ‘ -azido-3 ‘ -deoxythymidine-5 ‘ -triphosphate (AZTTP) are compounds that inhibit 
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telomerase activity and cause progressive telomere shortening in culture cell line 
models (Sharma et aL, 1997; Raymond et al.，1996; Strahl & Blackbum, 1996). 
Telomeric targeting agents include the G quartet interactive agents and inhibition of 
,. 
telomerase activity in a cell-free system is demonstrated using 7-deaza nucleotides 
(Sharma et aL, 1997). However, it should be taken into account that tumor cells 
might maintain their telomeres by telomerase independent mechanisms which 
would need to be inhibited as well. The potential toxicities and mechanisms of 
resistance using these therapies should be reviewed. 
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V.7. Future Direction  
Telomere and telomerase could be targets for cancer therapy. However, 
« t . 
many aspects of the complex biology and basic regulation of telomerase remain 
unresolved. More accurate methods for measuring telomere lengths, better 
telomerase extraction methods and identification of genes regulating the repression 
pathway of telomerase should be investigated. Beside, repression of telomerase 
activity in quiescent cells (Holt et al.，1996) suggests that different levels of 
telomerase in tumor biopsies may reflect the fraction of proliferating cells indicate 
that the need for the development of a telomerase assays for tissue samples in situ. 
Clearly, future experiments based on in situ expression of the R N A and 
protein as well as knockout of hTERT gene expression will help to clarify the 
prognostic potential of the hTERT gene in cancers. It is also crucial to leam if 
alternate hTERT-derived proteins are expressed in the cell and whether hTERT 
proteins lacking critical reverse transcriptase motifs can associate with hTR or 
hTEPl to modulate telomerase activity. It is recently reported that the 
phosphorylation of hTERT and hTEPl is a prerequisite for the activation of 
telomerase in an intact human breast cancer cell lines (Li et al., 1998). It is 
interesting to perform further investigation on it and the phosphorylation sites on 
hTERT and hTEPl have yet to be determined. Beside, the possible telomerase 
tumor suppressor gene or the regulation by some other oncogenes should be further 
investigated. 
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For the medical field, P K C a and tankyrase are the two new targets. Since 
P C K a may be involved in tumor development, it suggests a potential therapeutic 
> 
window for altering telomerase activity in anticancer therapy (Li et al., 1998). 
Besides, new anticancer agents that work by inhibiting tankyrase, thereby blocking 
telomerase activity and making cancer cells mortal again can be further examined 
(Smithetal.，1998). 
Extending life span of primary cells could significantly enhance the ability to 
grow cells ex vivo for autologous transplantation could be useful in growing extra 
skin cells for bum victims (Shay, 1997). Future strategies may include 
conventional chemotherapies to reduce tumor mass followed by a recovery period 
to permit renewed proliferation of primitive stem cells to replace damaged tissues 
(Shay, 1997). Other strategy include surgical removal of tumor, followed by 
combinatorial anti-telomerase therapy with conventional radiation and or 
chemotherapies. However, the potential effects of such telomerase inhibitors 
should be concerned. 
The issues about the alternative mechanism of lengthening in telomere and 
tumor proliferation in the absence of telomerase in the knockout mice are probably 
the most worth-noted (Niida et al., 1998). Direct telomere targeting appears as 
another therapeutic approach besides telomerase inhibitors. Therefore, it is 
appealing to develop drugs that can target telomeres directly in the future. 
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VI. CONCLUSION 
— M a ^ « M a ™ « M M ^ » ^ ^ a « M < ^ » ^ ^ ^ ^ ^ ^ ^ » « ^ ^ ^ ^ ^ ^ ™ ^ ^ ^ ^ » ^ ^ ^ ^ ^ ^ ^ » ™ * 
�. 
Multiple genetic changes are required for cancer development. Besides 
oncogenes and tumor suppressor genes or virus involved, telomerase is believed to 
be involved in tumorigenesis. Li this study, telomerase activity is examined in a 
broad range of gliomas. It was found out that telomerase activity was measured in 
grade II or higher grade gliomas but not in grade I gliomas. It was observed that 
telomerase activity expression frequencies seem to correlate with the tumor grading 
especially in oligodendroglial tumors. It suggested the role of telomerase 
activation in tumorigenesis. On the other hand, the similar expression frequencies 
in grade II, III and W astrocytomas suggested that telomerase activation was 
probably an early event in the molecular genesis of astrocytomas. 
Besides telomerase activity, telomere length in oligodendroglial and 
ependymal tumors was measured. Li general, there was no prominent correlation 
between mean TRF length and telomerase activity in our samples. However, a 
slightly shorter length was observed in telomerase-positive oligodendroglial 
tumors. ALT mechanisms were not prominent in our telomerase-negative 
samples. On the other hand, some of them showed a short telomere length 
suggested that there might be non-telomerase mechanism in maintaining telomere 
length not resulting in long telomere length. From this study, all the evidences 
showed that telomerase activation was not the only mechanism for telomere length 
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maintenance. Further studies should concentrate on those non-telomerase 
mechanisms to understand telomere length regulation. Besides, the unknown 
gene on chromosome 2 might provide a genetic direction on telomere length 
^. 
regulation. 
]n this study, telomerase associated protein hTEPl was widely expressed in 
both telomerase-positive and negative samples. The m R N A level of hTEPl was 
clearly not correlated to the telomerase activity. It is possible that the post-
transcripitional level rather than the transcriptional level involved in telomerase 
regulation. Besides, the possibility that it is the balance level between hTEPl and 
other telomerase component important in regulation rather than hTEPl alone 
cannot be excluded. In contrast to hTEPl, the catalytic subunit, hTERT, its 
transcriptional level was highly correlated to telomerase activity in our samples. 
However, the fact that some of the telomerase-negative tumor samples showed 
hTERT m R N A expression indicated that there are another mechanisms involved in 
telomerase regulation. For instance, alternate splicing of hTERT transcripts and 
the post-transcriptional control of hTERT are another proposed mechanisms. 
Besides telomerase components, the relationship between pl6 or pRb expression 
with telomerase activity was also examined. Although pl6 and pRb play an 
important role in the regulation of cell cycle, no correlation between their 
expression and telomerase activity was observed in our non-astrocytic samples. 
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As more research was progressing, the picture of telomerase or telomere in 
tumorigenesis becomes more complicated. It seems that it is not as simple as 
researchers thought a decade ago. Many other telomerase-related factors were 
， . 
discovered e.g. protein kinase Ca, Myc, tankyrase. Obviously there are many 
other unknown factors will be discovered later. It is important for us to leam 
more on telomerase because it is a good target on cancer therapy if all the theories 
are true. Telomerase inhibitors are the main therapeutic targets nowadays. 
Therefore, telomerase-related research is worthwhile to be continued and hopefully 
it can be widely applied for clinical use one day. 
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